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Abstract 
Abstract 
 
Hybridoma technology, developed in the mid-1970s by Köhler and Milstein, made it 
possible to produce limitless quantities of highly specific monoclonal antibodies 
(mAbs) that recognize specific epitopes of cellular antigens. This advance has led to 
invaluable insights into normal lymphocyte differentiation and has permitted the 
identification of the cellular origins of several lymphoid malignancies. Improved 
immunohistochemical techniques, using a wide variety of antibodies in combination 
with morphology and molecular studies, have not only facilitated diagnosis and 
dramatically improved the classification of lymphoid malignancies but also provide an 
additional tool to predict tumour response to therapy. 
In recent times, many studies have highlighted the rule of two helper T cell subtypes, 
regulatory T cells (Treg) and follicular helper T cells (TFH) as key players in tumour 
development and immunity. Both cell types have a variety of functions in T cell 
activation and in the maintenance of immune homeostasis, and they have been shown 
to play an important role in the development of autoimmune diseases as well as in 
cancer. Understanding the mechanisms by which Treg and TFH cells exert their influence 
in cancer is an area of intense research with broad implications for the development of 
therapeutic strategies. However, due to the lack of Treg and TFH specific markers, little 
was known about the presence or distribution of Treg and TFH in normal and tumoral 
tissues. 
To address these issues we have produced and characterized several monoclonal 
antibodies against the transcription factor FOXP3. We have identified and documented 
for the first time the expression of FOXP3 protein at single cell level in both lymphoid 
tissue and peripheral blood, showing that FOXP3 mAb is a specific and sensitive toll 
able to detect FOXP3 protein in a variety of commonly used immunological techniques. 
Because of the importance of FOXP3 in the development and function of Treg cells, we 
have analysed FOXP3 protein expression in 172 paraffin-embedded lymphoma samples. 
We found that FOXP3 in tumour cells was confined to adult T-cell 
leukaemia/lymphoma (ATLL) cases (17 out of 25 cases, 68%), while in the other 
lymphoma types analysed, FOXP3 expression was only detected in the reactive T cell 
population present in the tumour microenvironment. In a collaborative study we also 
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reported the presence of Treg in the lymphoid microenvironment. In contrast with most 
studies done in solid tumours, we found that an increased number of Treg is associated 
with prolonged survival in Hodgkin and follicular lymphomas, suggesting that FOXP3+ 
cells may act differently in this type of malignancies. 
In an effort to better define the expression and the diagnostic value of two TFH proteins, 
PD-1 and SAP, we have generated a specific mAb able to recognize PD-1 protein in 
paraffin embedded tissue and we have evaluated its expression in a large set of 
reactive and tumoral samples.  
The immunohistochemical analysis of more than 500 lymphoma biopsies showed that 
95% of the cases of angioimmunoblastic T-cell lymphoma (AITL) expressed at least one 
of these markers, providing additional evidence that AITL arises from TFH, and they are 
likely to be a valuable tool in the diagnosis of this disease. PD-1 and SAP were also 
expressed in a minority of cases of peripheral T cell lymphoma other than AITL, raising 
the possibility that such cases may be related in origin to germinal center helper T cells. 
We also reported that PD-1 is an excellent marker for the identification of the 
characteristic T-cell rosettes around the neoplastic B cells in nodular lymphocyte-
predominant Hodgkin lymphoma (NPHL).  We describe for the first time that the 
presence of PD-1 positive rosettes is not a unique feauture of NPHL, since we also 
found them in several cases of lymphocyte-rich classical Hodgkin lymphoma (LRCHL), 
suggesting a close biological relationship between these pathological entities. The 
presence of PD-1+ T-cell rosettes could be useful for the differential diagnosis of NLPHL 
and T cell /histiocyte-rich B cell lymphoma (THRBCL), which is usually a controversial 
and difficult task. 
In conclusion, the screening of antibodies in routine sections has once again proven to 
be a powerful approach for identifying diagnostic biomarkers.  
FOXP3 and PD-1 mAbs may help diagnostic pathologists in the identification of 
neoplastic T cells in routinely processed tissue samples and may also be used to 
achieve a better understanding of the pathogenic role of Treg and TFH cells in 
inflammatory and malignant diseases. 
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Resumen  
 
La técnica para la producción de hibridomas, desarrollada en la década de los 70 por 
Köhler y Milstein, ha permitido generar cantidades ilimitadas de anticuerpos 
monoclonales (mAbs) capaces de reconocer con alta afinidad epítopos específicos de 
diferentes antígenos celulares. Gracias a este gran avance tecnológico, ha sido posible 
esclarecer tanto el proceso de diferenciación de los linfocitos normales como la 
identificación del origen celular de la mayoría de las neoplasias linfoides. La mejora de 
las técnicas inmunohistoquímicas junto con el uso de un amplio panel de anticuerpos, 
en combinación con los estudios morfológicos y moleculares, han facilitado el 
diagnóstico, revolucionando la  clasificación de los linfomas y aportado una valiosa 
herramienta de apoyo pronóstico. Estudios recientes han destacado el papel 
fundamental realizado por dos subtipos de células T colaboradoras, las T reguladoras 
(Treg) y  las T colaboradoras del centro germinal (TFH), como actores principales tanto 
en la inmunidad como en el desarrollo de tumores. Ambos tipos celulares intervienen 
en la regulación de la activación de células T y en el mantenimiento de la homeostasis 
inmunológica. Recientemente se ha puesto de manifiesto la implicación directa de 
estos tipos celulares en el desarrollo tanto en enfermedades autoinmunes, así como 
en cáncer. La elucidación de los mecanismos por los que las células Treg y TFH actúan en 
diferentes neoplasias es un área de investigación con una gran proyección en el 
desarrollo de nuevas estrategias terapéuticas. Sin embargo, la carencia de marcadores 
específicos frente a las poblaciones linfoides Treg y TFH dificultaba la comprensión sobre 
su  presencia y distribución en tejido normal y tumoral.  
Dado que las técnicas inmunohistoquímicas son una potente herramienta para poder 
abordar estos problemas, hemos producido y caracterizado varios anticuerpos 
monoclonales frente al factor de transcripción FOXP3. Por primera vez hemos 
identificado y documentado la expresión de FOXP3 a nivel celular, tanto en el tejido 
linfoide como en sangre periférica, demostrando que al anticuerpo FOXP3 constituye 
un erramienta específica y sensible capaz de detectar la proteína con una gran 
variedad de técnicas inmunológicas de rutina. Debido a la importancia que FOXP3 
tiene en el desarrollo y función de las células Treg, hemos estudiado su expresión en 
172 muestras de linfoma fijadas y parafinadas. En tejido tumoral, su expresión se 
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encuentra restringida a la leucemia/linfoma de células T del adulto (ATLL) (17 de 25 
casos, un 68%). Sin embargo, en el resto de los tumores estudiados, la expresión de 
FOXP3 fue detectada en la población T reactiva presente en el microambiente tumoral. 
Este resultado fue corroborado en un estudio en colaboración con otros laboratorios, 
donde se confirmó la presencia de Treg en el microambiente linfoide. 
Sorprendentemente, a diferencia de la mayoría de los estudios realizados en tumores 
sólidos, se encontró que una mayor presencia de linfocitos Treg se asociaba a una 
mayor supervivencia en linfomas de Hodgkin y folicular, lo que sugiere que la las 
celulas FOXP3 actuan de manera diferentes en estos tipos de linfomas. 
Para poder definir con mayor precisión el patrón de expresión y el posible valor 
diagnóstico de las proteínas de PD-1 y SAP, marcadores especificosde la TFH, hemos 
generado un mAb específico capaz de reconocer la proteína PD-1 en tejido fijado y 
parafinado. Se ha evaluado su expresión en una extensa serie de casos tanto reactivos 
(no tumoral) como tumorales. El estudio inmunohistoquímico de más de 500 biopsias 
de linfoma reveló que el 95% de los casos de linfoma T angioinmublástico (AITL) 
expresaban al menos uno de estos marcadores, dato que refuerza la hipótesis de que 
los AITL derivan de las células TFH,  por lo que estos nuevos marcadores constituyen 
una valiosa herramienta diagnóstica para esta enfermedad. La expresión de PD-1 y SAP 
también se encontró en una minoría de casos de linfoma T periférico, sugiriendo la 
posibilidad de que estos casos se originen en las células TFH de centro germinal. Otro 
hallazgo fundamental ha sido la identificación de PD-1 como un excelente marcador de 
las rosetas de linfocitos T que rodean las céulas B neoplásicas, característica clave en el 
diagnóstico del linfoma de Hodgkin de predominio linfocítico (NPHL). Por primera vez 
se ha descrito que la presencia de rosetas PD-1+ no es una característica exclusiva del 
NPHL, sino que también se puede encontrar en un porcentaje elevado de linfomas de 
Hodgkin rico en linfocitos (LHCRL), lo que sugiere una estrecha relación biológica entre 
estas entidades.  La presencia de rosetas PD-1+ constituye además una ayuda adicional 
en el difícil diagnóstico diferencial entre LHPLN y linfoma B rico en células T/histiocitos 
(THRBCL), dado que hemos encontrado que todos los casos analizados de THRBCL 
carecen de rosetas PD1+.  
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En conclusión, el uso de mAbs en el diagnóstico histopatológico de rutina ha 
demostrado una vez más ser una potente herramienta para la identificación de 
biomarcadores diagnósticos. 
Los anticuerpos monoclonales FOXP3 y PD-1 han resultado ser unos excelentes 
marcadores para la identificación de las células Treg y TFH tanto en condiciones 
fisiológicas como patológicas, permitiendo un mejor conocimento del papel que estos 
linfocitos juegan tanto en procesos inflamatorios como en las enfermedades 
linfoproliferativas. 
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Abbreviations 
Abbreviations 
AITL  Angioimmunoblastic T-cell lymphoma  
APCs Antigen-presenting cells 
BCL6 B-cell lymphoma 6   
CXCR5 C-C chemokine receptor type 5 
CCR4 C-C chemokine receptor type 4 
CCR7 Chemokine (C-C motif) receptor 7 
CCL22 Chemokine (C-C motif) ligand 22 
CD25 Interleukin 2 receptor α –chain 
CD39 Ectonucleoside triphosphate diphosphohydrolase-1 
CD73 Ecto-5´-nucleotidase 
CHL Classical Hodgkin’s lymphomas 
CSTCL Cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma  
CTLA-4 Cytotoxic associated antigen-4 
DAB 3,3'-Diaminobenzidine  
DCs Dentritic cells  
ELISA  Enzyme-linked immuno-absorbant assay 
FCS Fetal calf serum 
FFPE Formalin-fixed paraffin embedded 
FOXP3 Forkhead box protein P3  
FL Follicular lymphomas  
FR4 Folate receptor 4 
GC Germinal center  
GEP Gene expressio 
GITR  Glucocorticoid-induced TNF receptor n profiling 
HAT Hypoxanthine, aminopterin and tymidine 
H&E Hematoxylin and eosin 
ICOS T-cell co-stimulator  
IDO Enzyme indoleamine 2,3-dioxygenase  
IL-10 Interleukin 10  
IL-2 Interleukin-2  
IL-21  Interleukin-21 
IL-2R Interleukin-2 receptor  
IL-35 Interleukin 35  
LRCHL Lymphocytes reach classical Hodgkin lymphoma 
IFN-γ Interferon-γ  
IPEX Immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
iTreg Inducible regulatory T cell 
MAb Monoclonal antibody  
MALT Mucosa-associated lymphoid tissue  
MHC II Major histocompatibility complex class II  
MCHL Mixed cellularity classical Hodgkin lymphoma 
NK Natural killer  
NLPHL Nodular lymphocyte-predominant Hodgkin lymphoma 
NSHL Nodular sclerosis Hodgkin lymphoma 
nTreg Naturally occurring regulatory T cells 
OMS Organización Mundial de la Salud 
PBS Phosphate-buffered saline 
PD-1 Programmed cell death 1  
PD-L1 Programmed death ligand 1  
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PD-L2 Programmed death ligand 2  
PTCLs Peripheral T cell lymphomas 
SAP Signalling lymphocytic activation molecule (SLAM)-associated protein  
SLAMF SLAM family members 
SDS-PAGE Sodium dodecyl sulfate–polyacrylamide gel  
TCR T cell receptor  
TGF-β Transforming growth factor beta  
TFH Follicular helper T cell  
Teff T effectors cells 
TH Helper T cell also called effector T cells 
TH1 T helper 1 
TH2 T helper 2 
TH17 T helper 17 
THRBCL T cell /histiocyte-rich B cell lymphoma 
TMA  Tissue microarrays  
Treg Regulatory T cell  
XLP Immunodeficiency X-linked lymphoproliferative disease  
WHO World Health Organization 
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Introduction 
1. T cell lymphomas: Seeking for new biomarkers  
 
The lymphoid malignancies are a heterogeneous group of disorders that occur as a 
result of neoplastic transformation of B and T lymphocytes at different stages of B- and 
T-cell differentiation. The wide variety of lymphoid malignancies reflects the various 
stages of lymphocyte development and the complexity of the immune system. The 
clinical and pathological characteristics of the lymphoid malignancies are collected in 
the World Health Organization Classification of Tumours of Haematopoietic and 
Lymphoid Tissues (WHO Classification) that uses all available information (morphology, 
cytochemistry, immunophenotype, genetics, and clinical features) to define clinically 
significant lymphoid entities (1). The WHO classification categorized lymphomas into 
three groups: B-cell neoplasms, T- and natural killer (NK) cell neoplasms and Hodgkin 
disease. 
In contrast to the major progress made in the knowledge and classification of B-cell 
lymphomas, advances in the field of T-cell lymphomas have been much slower, and 
dealing with this category of diseases currently remains a challenge from the 
therapeutical and pathobiological perspectives.  
Malignancies derived from mature T and NK cells (also called peripheral T cell 
lymphomas PTCLs), constitute a heterogeneous group of uncommon neoplasias, 
accounting about the 15% of all non-Hodgkin lymphomas worldwide. With few 
exceptions, PTCLs exhibit resistance to standard chemotherapy regimens and have a 
poor clinical outcome (2). 
The histopathological diagnosis of T cell lymphomas is often challenging due to a broad 
morphologic and immunophenotypic variability and the significant overlaps across 
distinct T cell entities (2).  
Recently, gene expression profiling (GEP) of this type of tumours has provided novel 
insights into the pathobiology of T cell lymphoma and led to the identification of novel 
biomarkers with diagnostic, prognostic or therapeutic implications (3, 4).  In detailed, a 
recent GEP study has been crucial in establishing molecular similarities between one of 
the most common PTCLs, angioimmunoblastic T-cell lymphoma (AITL),  and a subset of 
CD4+ T cell, normally located in germinal centre (follicular helper T cells (TFH) ) that 
exert helper functions to follicular B cells (5). 
 24 
 
Introduction 
In addition, several reports have highlighted the importance of another subset of 
helper T cells, called regulatory T (Treg) cells, in lymphomagenesis.  Treg has recently 
become the focus of interest, due to the critical role of these cells in the modulation of 
immune responses, particularly in the suppression of tumor-associated antigen-
reactive lymphocytes and consequently in cancer immunity (6).  
The identification and the production of specific markers able to identify specific T cells 
lineage could be extremely useful to better understand the role that T cells subtypes, 
such as Treg or TFH, play in tumour development and in tumour microenvironment. 
The ability to diagnose and classify lymphoid malignancies improved substantially in 
the 1980s thanks to the work of Professor David Mason and others (7) that developed 
an immunopathological method utilizing a wide variety of monoclonal antibodies 
(mAbs) against lymphoid cell surface antigens. This novel methodology was adapted to 
routine formalin-fixed paraffin embedded (FFPE) sections making a dramatic impact in 
pathology (8). 
This technology was rapidly adopted by pathologists both at academic centres and in 
hospitals and is currently used, in conjunction with morphology and molecular studies, 
for the classification and diagnosis of lymphoid malignancies. 
The aim of this thesis is the production of new cell lineage and differentiation markers 
specific for T cells (Treg and TFH). These mAbs will help to reveal the tumour’s biological 
behaviour and will allow the detection of this cell types in paraffin tissue samples. This 
new markers may also help to refine the diagnostic and prognostic stratification of the 
patients with T cell lymphomas. 
 
2. Helper T cells (TH) 
 
CD4+ T cells represent one of the main components of the adaptive immune response. 
These cells control the functional activities of both innate and adaptive immunity and 
determine the outcome of the immune response against infections. These cells do not 
have any cytotoxic activity per se and do not kill infected cells or clear pathogens 
directly. They instead control the immune response by directing other cells to perform 
these tasks. 
Naïve T cells enter secondary lymphoid organs in the T cell zones and after the 
interaction with antigen-presenting cells (APCs), they can differentiate into subsets of 
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helper (effectors) CD4+ T cells (TH) (TH1, TH2, TH17, and Treg) (9). Each subset is defined 
and controlled by a unique master regulator transcription factor (T-bet, GATA3, RORgt 
and FOXP3, respectively (10)) and  by the production of a unique set of cytokines. 
TH1 cells characteristically produce interleukin-2 (IL-2) and interferon-γ (IFN-γ); they 
induce macrophage activation and are very effective in controlling infection by 
intracellular pathogens. In contrast, TH2 cells secrete interleukin-4, interleukin-5, and 
interleukin-13, and are excellent helpers for B cells in producing antibodies. TH17 cells, 
which owe their name to their production of interleukin-17, are critical for host 
defence against bacterial, fungal and viral infections (11). 
Another highly specialized subpopulation of TH cells is that of regulatory T cells (Treg), 
which are responsible for the maintenance of immunological self-tolerance by actively 
suppressing self-reactive lymphocytes. It is now recognized that Treg have a crucial role 
in the maintenance of peripheral self-tolerance, transplantation, allergy and tumour 
and microbial immunity (12). 
Recently, a fifth subset of effectors TH cells, called follicular helper T cell (TFH) cells has 
been discovered and studied. This cell type is characterized by their location in the 
germinal centres of secondary lymphoid organs and by their ability to interact with B 
cells, supporting B-cell survival and antibody responses (13). 
In recent years, an increasing attention has been paid to the role of TFH and Treg in 
regulating the immune response in normal and pathological conditions, suggesting 
that Treg and TFH may be excellent targets for the investigation, diagnoses, treatment 
and prevention of immunological disorders. 
 
3. Regulatory T cells (Treg) 
3.1 Treg and FOXP3  
Immunological tolerance requires a controlled balance between maintaining 
peripheral tolerance to auto antigens and preserving the potential to initiate 
protective immune responses against infectious agents. To achieve a fine balance 
between these two different immunological outcomes, a network of Treg is necessary.  
Treg are cells specialized in suppressing excessive or misguided immune responses that 
can be harmful to the host, for example in autoimmune diseases, allergy or in certain 
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inflammatory diseases (14). On the other hand, an increased Treg response can hamper 
host protective immunity in infectious diseases and cancer (15). 
In normal individuals, Treg represent about 5-10% of total CD4+ T cells in thymus, 
peripheral blood, and lymphoid tissues and are distinguished by their expression of 
interleukin 2 receptor α -chain (CD25) and the transcription factor forkhead box 
protein P3 (FOXP3).  
The importance of this cell type was made evident by the fact that the depletion of this 
population in normal rodents produces a variety of autoimmune inflammatory 
diseases, whereas reconstitution with CD4+ CD25+ T cells can inhibit disease 
development (16). 
The identification of FOXP3 as the master regulator gene for Treg has helped in the 
understanding the function and this cell type. Humans with a mutation in the FOXP3 
gene develop IPEX syndrome (immunodysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome). This is a severe multiorgan autoimmune disease 
characterized by type-1 diabetes, inflammatory bowel disease and severe allergy (17, 
18). Similarly, scurfy mice, which lack FOXP3 expression, develop a lethal autoimmune 
syndrome (19). Further evidence for FOXP3 as a key controller of the development and 
suppressive function of Treg, come from experiments in which transduction of the gene 
is sufficient to convert naïve T cell into Treg-like cells (20).  
FOXP3 is able to control the expression of several characteristic genes coding for cell 
surface molecules, such as CD25, the glucocorticoid-induced TNF receptor (GITR) and 
the cytotoxic associated antigen-4 (CTLA-4), and together with other proteins, is 
responsible for the repression of IL-2 and other cytokine genes (21). The indispensable 
role of FOXP3 for the control of these autoimmune and inflammatory disorders 
underlines the crucial importance of FOXP3+ Treg for self-tolerance and immune 
homeostasis.  
 
3.2 Markers of Treg 
Treg are classically defined by their constitutive expression of CD25. Among the other 
major surface markers, CTLA-4, GITR, CD39 (ectonucleoside triphosphate 
diphosphohydrolase-1) and CD73 (ecto-5´-nucleotidase) are the most important 
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markers with respect to development and function of Treg (22). However, none of these 
markers are really specific, as they can also be expressed in activated T cells. At the 
moment, the expression of the transcription factor FOXP3 is the most definitive 
signature of Treg. 
 
3.3 Treg development 
Treg, like all T cells, arise from progenitor cells in the bone marrow and either develop 
in the thymus (naturally occurring Treg, nTreg) or can be induced by other T cells in the 
periphery (inducible/adaptive Treg, iTreg) (Figure 1). nTreg develop directly from CD4+ T-
cell precursors by a process of positive selection through their interaction with thymus 
epithelium and dentritic cells (DCs) in the presence of major histocompatibility 
complex class II (MHC II) and self-peptide. These nTreg, constituting 5-10% of total 
lymphocytes, then enter peripheral circulation and are widely distributed in peripheral 
lymph nodes and spleen (23) where they act to control self-reactive T cells that have 
escaped thymic negative selection. nTreg have a polyclonal T cell receptor (TCR) 
repertoire that allow them to recognize a wide spectrum of self and non-self antigens 
(24).  
In recent years it has become evident that FOXP3+ Treg could also be generated outside 
the thymus under a variety of conditions. The iTreg development in vivo is still not well 
understood, but it is known that iTreg could be derived from naive T cells under the 
influence of various inductive signals such as TCR or cytokines such as the transforming 
growth factor beta (TGF-β) and IL-2 (Figure1). Under these conditions, iTreg mature in 
peripheral sites, including mucosa-associated lymphoid tissue (MALT), where they 
acquire the expression of markers typical of Treg, including CD25, CTLA4 and GITR. 
Upon upregulation of the transcription factor FOXP3, Treg start to exert their 
suppressive effect. This includes the secretion of cytokines including interleukin-10 (IL-
10) and TGF-β, which may induce cell-cycle arrest or apoptosis in effector T cells 
(TH1,TH2 and TH17), and block co-stimulation and maturation of DCs (25). iTreg are 
essential in mucosal immune tolerance and in the control of severe chronic allergic 
inflammation, and most likely they are one of the main barriers to the eradication of 
tumours (26). 
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Figure 1. Treg development 
Hematopoietic progenitors are generated in the bone marrow and then travel to the thymus. In the 
thymus, high affinity TCR-MHC interactions promote the generation and expansion of natural regulatory 
T cells (nTreg) that are released into circulation. In the periphery iTreg cells are originated by FOXP3- CD4+ 
naïve T cells in the presence of cytokines such as TGF- and IL2. Treg then suppress the activation and 
proliferation of many cell types including TH1, TH2, and TH17 cells. 
 
3.4 Treg function  
FOXP3+ Treg can both directly and indirectly suppress the activation and proliferation of 
many cell types, including other T cells, B cells, DCs and NK cells. Although many 
possible mechanisms for Treg-mediated suppression have been proposed in the past, 
the suppressive activity of Treg remains poorly understood. 
Several in vivo and in vitro findings indicate that Treg suppression may operate either in 
a contact-independent or dependent manner (27) (Figure 2). One mechanism of 
contact-independent suppression has been described in several reports indicating that 
cytokines such as interleukin 10 (IL-10), interleukin 35 (IL-35) and TGF-ß are needed to 
mediate suppression (28). IL-10 and TGF-ß cytokines hamper the antigen presenting 
ability by down-regulating the MHC class II and co-stimulatory molecules on DCs, thus 
preventing the maturation and activation of DCs cells both in humans and in mice (29) 
(Figure 2A). 
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Figure 2. Basic mechanisms of Treg suppression 
A: Treg secrete suppressor cytokines that can directly inhibit effector T cells (Teff) function B: Activated 
FOXP3+ Treg may function as cytotoxic cells expressing granzymes and kill Teff cells. In addition, CD25 and 
the IL-2 receptor α chain, has the capacity to compete with Teff cells for IL-2, resulting in reduced 
activation and expansion of T cells. C: Treg can deliver a negative signal to Teff cells through up-regulation 
of intracellular cyclic AMP, which leads to inhibition of T cells. D: CD80/CD68 molecules expressed by 
antigen presenting cells (APC) interact with CTLA-4 on Treg resulting in IDO production leading to 
immunosuppressive effects.  
 
Cytosolic activity has also been proposed as a possible mechanisms used by Treg to 
suppress immune response. After activation, Treg may express granzymes and kill 
activated CD4+ and CD8+ T cells by a perforin dependent mechanism (30) (Figure 2B). 
In addition, there is a possibility that the lack of production of IL-2 by FOXP3+ Treg, 
together with a high expression of IL-2 receptor (IL-2R), makes Treg able to exhaust IL-2 
from the surrounding microenvironment, thereby contributing to reduce the activation 
and expansion of effector T cells (Teff) (31).  
In addition to contact-independent suppression, other mechanisms of contact-
dependent suppression by Treg have been proposed. Thus, Treg can deliver a negative 
signal to effector T cells (Teff) through up-regulation of intracellular cyclic AMP, which 
leads to inhibition of T cell proliferation and IL-2 formation (Figure 2C)(32). Treg can also 
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interact with APC cells through CTLA4/CD80/CD86 interaction, resulting in the 
induction of the enzyme indoleamine 2,3-dioxygenase (IDO), which is a potent 
immunosuppressive molecule (33) (Figure 2D). 
Taken together, these findings suggest that multiple mechanisms may operate in Treg 
mediated suppression and that various molecules may be secreted or expressed on the 
cell surface of Treg and directly contribute to their suppressive functions. 
Understanding the mechanisms by which Treg exert their influence is an area of intense 
research with broad implications for the development of therapeutic strategies for 
many disease processes including cancer, diabetes, and immune mediated diseases. 
 
3.5 Treg and cancer  
Understanding the mechanisms of tumour tolerance is a major challenge for cancer 
research. It is becoming increasingly clear that Treg play an active and significant role in 
the progression of cancer, and have an important role in suppressing tumour-specific 
immunity (23, 34). 
Over the last years a number of reports have described the presence of tumour-
specific immune cells in various mouse and human malignancies (35). In the presence 
of Treg, the immune system frequently fails to prevent tumour formation and 
metastasis, and it can contribute to tumour growth and progression. In breast (36), 
ovarian (37) and gastric cancer (38), the presence of high number of infiltrating Treg 
have been associated with poor survival and tumour relapse. Also, targeting Treg by 
administration of a CD25 monoclonal antibody abrogated immunologic 
unresponsiveness to tumours and induced spontaneous development of tumour-
specific CD8+ Teff cells and NK cells (23). 
Regarding how Treg population increases in tumours, several possibilities have been 
postulated. One of the possible mechanisms for Treg cells recruitment to the tumour 
site may involve the production of the chemokine (C-C motif) ligand 22 (CCL22) by 
tumour cells and tumour infiltrating macrophages, which chemoattract and recruit 
CD4+ CD25+ Treg expressing C-C chemokine receptor type 4 (CCR4) (Figure 3). On the 
other hand, an increased Treg recruitment could be promoted by proliferating and 
dying tumour cells that provide a large amount of self-antigens (39). 
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It is also likely that FOXP3+ Treg may be derived from naïve CD4 T cells due to high 
concentrations of TGF-β secreted by tumour cells or DCs present in tumours (40).  
Finally, Treg can inhibit the generation of Teff cells, resulting in the induction of 
tolerance against the tumour. 
 
 
 
Figure 3. Treg suppress antitumor immune responses 
Both tumour cells and tumour-associated macrophages produce the chemokine CCL22 that attract Treg 
through the CCR4 receptor, leading to the accumulation of Treg in the tumour microenvironment (Treg 
migration). Treg receive proliferative signals (iTreg expansion) through the presence of tumour-associated 
self-antigens and high levels of TGF-β cytokine. Also, dendritic cells (DCs) may further enhance Treg 
expansion. The increased number of Treg inhibits natural killer cells (NK), natural killer T cells (NTK), CD8+ 
cytotoxic T lymphocytes (CTL) and CD4+ helper T cells, and could contribute to tumour progression. This 
image was modified from reference (41).   
 
The effect that Treg play on tumour-specific T cell immunity in lymphomas is less well 
established. Recent evidence suggests that the cellular composition of the tumour 
microenvironment, particularly the quantity of tumour-infiltrating Treg, can significantly 
modify the clinical outcome in hematologic malignancies. Contrary to what has been 
observed in solid tumours, in classical Hodgkin’s lymphomas (cHL) (42) and in follicular 
lymphomas (FL) (43), the presence of a high number of Treg correlate with better 
response and improved survival. These studies suggest that tumour-infiltrating Treg in 
Introduction 
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lymphoma may act to suppress not only tumour-infiltrating cytotoxic cells, but also the 
malignant cells. The implication of Treg in the behaviour and development of these 
pathologies may be therefore more complex than for solid tumours, and has to be 
further investigated. 
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4. Follicular helper T cells (TFH) 
4.1 Follicular helper T cells as a distinct TH subset 
TFH are essential moderators of the immune response. Although they do not have the 
capability to directly target invading pathogens, they can orchestrate a coordinated 
response from many other cell types. 
TFH are a subset CD4+ T cells localized in the B cell follicles of secondary lymphoid 
organs such as lymph nodes, spleens and Peyer's patches. TFH are best defined by their 
expression of the C-C chemokine receptor type 5 (CXCR5) that allows them to migrate 
into the B cell follicles of secondary lymphoid tissues, where they provide help for the 
differentiation of B cells (9, 10). Gene expression analysis of purified Teff cells 
expressing high levels of CXCR5 revealed 
a strikingly different gene expression 
profile from TH1, TH2, TH17 and Treg, 
supporting the theory that TFH are a 
distinct subset of CD4+ T cells (44, 45). 
Compared to other T-cell subsets, TFH 
cells show a unique transcript signature 
characterized by the expression of CD4, 
CD10, CXCR5, B-cell lymphoma 6 (BCL6), 
CD40L and CD57 (which are also present 
in B-cells and other types of T-cells) and 
by molecules that appear to be more 
restricted to TFH cells (Figure 4). The 
molecules hat are important for the role 
of TFH cells helping B cells differentiation 
in germinal-centers include the inducible 
T-cell co-stimulator (ICOS), signaling 
lymphocytic activation molecule (SLAM)-
associated protein (SAP) and 
programmed cell death 1 (PD-1) (Figure 
4). The transcription factor BCL6 and the 
 
Figure 4. Interaction between TFH and B cells 
Interactions between TFH and B cells are 
mediated by an array of accessory molecules, 
including ICOS, PD-1, CD40L and SAP on TFH, and 
by ICOSL, PD1L, CD40 and the SLAM family of 
receptors (CD84) on B cells. TFH are also 
characterized by the expression of BCL6 protein 
and the production of IL-21. 
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cytokine IL-21 have also important roles in TFH cell differentiation and function, and 
both of them are now considered hallmarks of this cell type. 
 
4.2 TFH development  
The mechanism of TFH cell generation, including the signals required for TFH cell 
differentiation and the time at which TFH cell differentiation occurs, are still not well 
understood. One of the possible scenarios is illustrated in Figure 5.  
 
 
Figure 5. Multiple steps for the generation of TFH  
In the T cell zone of secondary lymphoid organs, DCs cells activate naive CD4+ T cells. T cell receptor 
signals, together with co-stimulation provided by CD28/B7, CD40L/CD40, ICOS/ICOSL and PD-1/PD-1L 
interactions are able to initiate the program of TFH differentiation. Increased expression of CXCR5 helps 
TFH to localize to B-T cell border where they interact with B cells trough CD40L/CD40, ICOS/ICOSL, 
CD84/SAP and PD-1/PD-1L. TFH then migrate in the GC where they provide help for the differentiation of 
B cells. 
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Upon antigen encounter, DCs migrate from the periphery to the T zone of the 
lymphoid tissue, where they present the antigen, by means of peptide MHC class II 
complex. 
Naïve CD4+ T cells, with a T cell receptor (TCR) specific for the presented antigen, will 
form a stable contact with the DCs and receive signals through co-stimulation provided 
by CD28/B7, CD40L/CD40, ICOS/ICOSL and PD-1/PD1L interaction, and by the up-
regulation of the transcriptional repressor BCL6 (46). As they do this, activated T cells 
down regulate the chemokine C-C motif receptor 7 (CCR7) and up-regulate CXCR5, and 
then move towards the follicle to the T-B border where they encounter B cells and will 
receive a second round of activation signals (25).  
The importance of B cells in TFH development is demonstrated by the lack of TFH in the 
absence of B cells, or when their interaction is abolished (47). Stable contacts between 
T and B cells in the T-B cell border are initially mediated through TCR and peptide MHC 
complex. Once again, a range of cell surface receptors interaction including 
CD40/CD40L, ICOS/ICOSL, SLAM family members (SLAMF) on both cell types, and PD-
1/ PDL1 are crucial to complete and maintain TFH differentiation (48).  
These interactions culminate in the secretion of cytokines by TFH, particularly IL-4 and 
IL-21, and the migration of TFH into the germinal centre (GC) (49). Activated T cells that 
fail to get the necessary signal do not enter the follicles. 
 
4.3 SAP and PD-1 in TFH cell development 
It has also become clear that the SLAM family of surface receptors play an important 
role in TFH generation. The importance of these molecules in T-B interactions first came 
to light in patients suffering from the immunodeficiency X-linked lymphoproliferative 
disease (XLP). XLP is caused by mutations in the gene encoding SAP (SH2D1A), a 
cytoplasmic adaptor molecule that signals downstream of the SLAM family of 
receptors. Patients with XLP, as well as gene-targeted KO mice that lack SAP 
expression, display a deficiency in T-dependent B cell responses (50, 51). 
Several recent studies have demonstrated that SAP, acting downstream of CD84, is 
required to regulate adhesion between T and B cells. Therefore, in the absence of SAP 
or CD84, CD4+ T cells are unable to form stable conjugates with B cells, and this leads 
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to a decrease in signals from TFH co-stimulatory molecules and cytokines, which 
directly impact B cell differentiation and survival (52). 
Another molecule highly expressed by TFH is PD-1 (CD279). PD-1 molecule and its 
ligands, programmed death ligand 1 and 2 (PD-L1 and PD-L2) have an important 
inhibitory function in the regulation of immune homeostasis and in the maintenance of 
peripheral tolerance (53). Evidence that PD-1 suppresses activation of the immune 
response comes from studies in which PD-1-deficient mice develop spontaneous 
autoimmune diseases such as systemic lupus erythematosus, some dilated 
cardiomyopathy, rheumatoid arthritis and type1 diabetes mellitus, due to the 
uncontrolled persistent T cell activation (54).  
Although PD-1 is highly expressed in TFH, little is known about its role in the 
development or function of this cell type. PD-1 is expected to provide an inhibitory 
signal to TFH, preventing excess of CD4+ T cells proliferation in the GC (55, 56).  
Additionally, it is thought that the induction of PD-1 by TFH cells within the GC 
promotes survival and selection of B-cells with high affinity immunoglobulin receptor 
(57). 
 
4.4 TFH function 
TFH are distinguished from other helper subsets by their unique ability to localise into B 
cell follicles and by their capacity to provide help to B cells to support their activation, 
expansion, differentiation and GC formation (58). 
The best-characterized B cell helper signal provided by TFH cells is through CD40L, 
which is highly expressed in these cells. CD40L is a potent activator of B cells and is 
able to induce proliferation and, in combination with cytokines, isotype switching and 
B cell differentiation (59). The importance of this molecule for B cell responses has 
been demonstrated in mice lacking CD40 or CD40L, which display abortive B cell 
responses and a failure to generate GCs and long-term memory B cells (60). 
Another mechanism by which TFH regulates B cell responses is through the secretion of 
cytokines. TFH are characterized by expression of IL-21, a cytokine capable of 
modulating B cell differentiation and proliferation (61). Recently, other cytokines (IL-4, 
IL-10, IL-17 and IFN-γ) have been described to be secreted by TFH and to play a role in 
isotype switching and antibody production (62) 
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4.5 Implications of TFH cells in lymphomas 
It is now well established the important role that TFH play in the GC microenvironment 
and in B cell development, and there is also emerging evidence that the aberrant 
accumulation or deregulation of TFH can also lead to autoimmune disorders (63).  
Recent studies are also suggesting that TFH cells may be important players in the 
biology of the tumour development and in particular in lymphoproliferative disorders 
(64). 
The GC microenvironment is not only an essential niche for generation of B-cell 
response, but it is also considered to be critical in the development of most human 
lymphoid neoplasms. Although most lymphomas originating from GC lymphocytes are 
B-cell lymphomas, it has been suggested that some peripheral T-cell lymphomas, in 
particular AITL, may arise from GC TFH cells. These results have been confirmed by GEP 
expression profiling studies carried out on peripheral T-cell lymphomas, which have 
identified that TFH represent the putative cell of origin of AILT, being both PD-1 and 
CXCL13 identified as markers for this T cells subset (44). 
Recent studies have highlighted that TFH markers are not exclusive of AITL, since they 
can also identify tumour cells in other type of T cell lymphomas such as cutaneous 
CD4+ small/medium-sized pleomorphic T-cell lymphoma (CSTCL). This finding suggests 
that similar process of lymph node B-cell stimulation by FTH could also take place 
outside the GC (65). 
In recent years, several studies have highlighted the presence of TFH cells in the 
microenvironment of a variety of B cell lymphomas, stressing the importance of the 
identification of TFH as an additional tool for lymphoma diagnosis (64). In addition, the 
presence of specific TFH in the tumour microenvironment could directly influence the 
tumour development and could help in predicting the response to treatment and 
survival (64). An example is the presence of TFH cells in nodular lymphocyte-
predominant Hodgkin lymphoma (NLPHL), a slow-growing type of lymphoma 
characterized by the presence of a small population of neoplastic B cells within a 
lymphocyte and histiocyte rich background. The distribution of TFH cell in this type of 
tumours is not random, since PD-1positive TFH cells form rosettes around the 
neoplastic B cells, where they are likely supporting tumour growth and survival (66). 
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Follicular lymphoma (FL) is a neoplasm derived from follicular GC cells, where tumour 
cells proliferate in follicular structures in close association with TFH and follicular DCs 
(67). A recent study has demonstrated that the number of PD1 positive cells infiltrating 
the tumour is a predictor of survival in patients with FL, suggesting that PD-1 is able to 
identify an important subset of TFH in the microenvironment of FL that could directly 
participate in the modulation of the tumour cell behaviour and consequently influence 
clinical evolution (68) 
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1. Linfomas T: Búsqueda de nuevos biomarcadores 
 
Los linfomas son un grupo heterogéneo de tumores que se originan como resultado de 
la transformación neoplásica de los linfocitos B y T durante diferentes estadios de su 
diferenciación celular. La gran variedad de neoplasias linfoides existente constituye un 
reflejo de las diferentes etapas de desarrollo linfocitario y de la complejidad del 
sistema inmune. Las características clínicas y patológicas de las neoplasias linfoides se 
encuentran recogidas en la clasificación de la Organización Mundial de la Salud (OMS) 
de los tumores de tejidos hematopoyéticos y linfoides, que utiliza la información 
disponible (morfológica, citoquímica, inmunofenotípica, genética y clínica) para definir 
las distintas entidades linfoides con significado clínico (1). La clasificación de la OMS 
divide los linfomas en tres grupos: linfomas de células B, linfomas de células T y 
“natural killer” (NK) y linfomas de Hodgkin.  
A diferencia de los importantes avances alcanzados en el conocimiento y clasificación 
de los linfomas de células B, el progreso realizado en el campo de los linfomas de 
células T ha sido mucho más lento, por lo que hacer frente a este tipo de linfomas 
sigue siendo un reto, tanto desde el punto de vista diagnóstico, como histopatológico y 
terapéutico.  
Las neoplasias malignas derivadas de las células T maduras y NK (también llamados 
linfomas T periféricos (PTCL)), constituyen un grupo heterogéneo de neoplasias poco 
frecuentes, representando alrededor del 15% de todos los linfomas no Hodgkin en 
todo el mundo. Además, con pocas excepciones, los PTCL son resistentes a los 
protocolos clásicos de quimioterapia y muestran una peor evolución clínica (2). 
El diagnóstico histopatológico de los linfomas T es a menudo difícil, debido a la amplia 
variedad morfológica, inmunofenotípica y a los solapamientos existentes entre las 
diferentes entidades de células T (2). De forma reciente, mediante perfiles de 
expresión génica se han obtenido nuevos conocimientos sobre la biopatología de los 
linfomas T, que han conducido a la identificación de nuevos biomarcadores con 
relevantes implicaciones diagnósticas, pronósticas y terapéuticas (3, 4). Basándose en 
este tipo de estudios, se han identificado marcadores específicos del subtipo más 
común de PTCL, el linfoma T angioinmunoblástico (AITL). De forma más concreta, se ha 
identificado como célula de origen del mismo un subtipo de células T CD4+ 
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denominada célula T colaboradora folicular (TFH). Estos linfocitos se localizan en el 
centro germinal (GC) realizando funciones auxiliares sobre los linfocitos B foliculares 
(5). 
Así mismo, varios estudios han puesto de relieve la importancia de otro subtipo de 
células T CD4+ en los procesos linfoproliferativos, las células T reguladoras (Treg). Este 
subtipo celular se ha convertido en un foco de interés debido a la función que ejercen 
en la modulación de la respuesta inmune, concretamente en la supresión de los 
linfocitos antígeno-reactivos asociados al tumor (6). La identificación y producción de 
marcadores específicos capaces de identificar los subtipos celulares T podría ser muy 
útil para ayudar a discernir el papel que juegan las células Treg y TFH en el desarrollo 
tumoral. 
La calidad diagnóstica y la posibilidad de clasificación de los tumores linfoides 
mejoraron sustancialmente en la década de los 80 gracias a la labor de numerosos 
investigadores, destacando entre ellos el profesor David Mason (7), gracias a cuyos 
trabajos se desarrollaron métodos inmunohistoquímicos empleando una amplia 
variedad de anticuerpos monoclonales contra antígenos linfoides de la superficie 
celular. Esta nueva metodología se adaptó a la rutina de laboratorio empleando 
muestras fijadas en formol e incluidas en parafina (FFPE), lo que implicó un gran 
avance en la histopatología (8).  
Esta tecnología fue rápidamente adoptada por los patólogos, tanto en centros 
académicos como en hospitales y se utiliza en la actualidad, junto a la morfología y a 
los estudios moleculares, para la clasificación y diagnóstico de las neoplasias linfoides.  
El objetivo de esta tesis es la identificación de nuevos marcadores de diferenciación 
específicos de linfocitos T y en concreto de las células Treg y TFH. Los anticuerpos 
obtenidos frente a estos marcadores serán fundamentales para estudiar el 
comportamiento biológico del tumor y permitirán la detección de estos subtipos 
celulares en muestras de tejido FFPE. Así mismo, estos nuevos marcadores podrán 
ayudar tanto en el diagnóstico como en el pronóstico de los pacientes con linfoma T. 
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2. Linfocitos T colaboradores (TH) 
Las células T CD4+ constituyen uno de los principales componentes de la respuesta 
inmune, controlando los procesos asociados a dicha respuesta contra las infecciones. 
Estas células no tienen actividad citotóxica ni son responsables de eliminar las células 
infectadas o los patógenos de forma directa, sino que estimulan a otras células para 
realizar dichas funciones. 
Los linfocitos T “naive” o vírgenes acceden a los órganos linfoides secundarios, en las 
áreas donde se localizan las células T, y tras la interacción con las células 
presentadoras de antígeno (APC), se diferencian en distintas subpoblaciones de 
linfocitos T colaboradores (efectores) CD4+ (TH), denominados TH1, TH2, TH17 y Treg (9). 
Cada subpoblación está genéticamente regulada por un único factor de transcripción 
“master” o patrón (T-bet, GATA3, RORgt y FOXP3 respectivamente (10)) y por la 
producción de un conjunto de citoquinas específicas. 
Las células TH1 producen interleuquina-2 (IL-2) e interferón-γ (IFN-γ), las cuales inducen 
la activación de macrófagos y son muy eficaces en el control de las infecciones 
producidas por patógenos intracelulares. Por otro lado, las células TH2 secretan IL-4, IL-
5 e IL-13 y son excelentes colaboradoras de las células B en la producción de 
anticuerpos. Las células TH17, denominadas así dada su producción de IL-17, son 
fundamentales para la defensa del huésped contra las infecciones bacterianas, 
fúngicas y virales (11). 
Otra subpoblación muy especializada de células TH, es la constituida por las células T 
reguladoras (Treg), un subconjunto de linfocitos T responsable del mantenimiento de la 
auto-tolerancia inmunológica mediante la supresión de los linfocitos auto-reactivos. 
Actualmente se sabe que las Treg tienen un papel crucial en el mantenimiento de la 
auto-tolerancia periférica, los trasplantes, la alergia y la inmunidad tumoral y 
microbiana (12). 
De forma reciente ha sido descubierta una quinta subpoblación de células T 
colaboradora, las denominadas células T colaboradoras foliculares (TFH). Este tipo de 
células se caracteriza por su localización en los GC de los órganos linfoides secundarios 
y su capacidad de interactuar con las células B, interviniendo tanto en la supervivencia 
de las mismas como en la respuesta mediada por anticuerpos (13). 
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En los últimos años se ha prestado una mayor atención al papel de las células TFH y Treg 
en la regulación de la respuesta inmune tanto en condiciones fisiológicas como 
patológicas, siendo estas células excelentes candidatas para la investigación, 
diagnóstico, tratamiento y prevención de determinados trastornos inmunológicos. 
 
3. Células T reguladoras (Treg) 
3.1 Treg y FOXP3 
El mantenimiento de la tolerancia inmunológica requiere la existencia de un equilibrio 
entre el mantenimiento de la tolerancia periférica a los antígenos propios y la 
respuesta inmunitaria protectora contra agentes infecciosos. Para lograr un buen 
equilibrio entre estos dos procesos es necesaria la existencia de los linfocitos Treg. 
Los linfocitos Treg están especializados en la supresión de la respuesta inmune excesiva 
o anómala que puede llegar a ser dañina para el huésped al derivar en procesos 
patológicos tales como enfermedades autoinmunes, alergias y determinadas 
enfermedades inflamatorias (14). Por otro lado, una respuesta exagerada por parte de 
los mismos puede llegar a alterar la función inmunológica “habitual” del huésped 
frente a enfermedades infecciosas y al cáncer (15). 
En los individuos sanos, las células Treg representan el 5-10% del total de las células T 
CD4+ de timo, sangre periférica y tejidos linfoides. Estas células se caracterizan por la 
expresión, tanto del  receptor α de la interleuquina 2 (CD25) como del factor de 
transcripción FOXP3 (forkhead box protein P3). 
La importancia de este tipo de células se hizo patente al observar que la disminución 
de esta población en roedores producía una gran variedad de enfermedades 
inflamatorias autoinmunes, mientras que la reconstitución con células T CD4+ CD25+ 
inhibía el desarrollo de dichas enfermedades (16). 
La identificación de FOXP3 como el gen regulador “master” de las células Treg ha 
contribuido a la comprensión y al estudio de la función de este tipo de linfocitos.  
En humanos, la mutación del gen FOXP3 se ha asociado al desarrollo de un síndrome 
denominado IPEX (Inmuno-desregulación, Poliendocrinopatía y Enteropatía ligada al 
cromosoma X), una severa enfermedad multiorgánica y autoinmune caracterizada por 
diabetes tipo 1, enfermedad inflamatoria intestinal y alergia severa (17, 18). De forma 
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similar, los ratones “scurfy”, que carecen de la expresión de la proteína FOXP3, 
desarrollan un síndrome autoinmune letal (19). El papel clave de FOXP3 en el 
desarrollo y función supresora de las Treg  ha sido ulteriormente confirmado en 
experimentos en los que la traducción del gen FOXP3 es suficiente para convertir 
células T “naive” o vírgenes en células con funciones similares a la Treg (20). 
Además, FOXP3 es capaz de controlar la expresión de varios genes de moléculas de 
superficie, tales como CD25, la familia de genes reguladores GITR (Glucocorticoid-
Induced TNF Receptor) y CTLA-4 (CTL-associated Antigen-4), y junto con otras proteínas 
es responsable de la represión de los genes de la IL-2 y otras citoquinas (21). 
Todos los estudios realizados hasta la fecha demuestran el papel fundamental de 
FOXP3 en el control de las enfermedades autoinmunes e inflamatorias y subrayan la 
importancia crucial de las células Treg CD4+ FOXP3+ en la auto-tolerancia y la 
prevención de enfermedades autoinmunes. 
 
3.2 Marcadores de las células Treg 
Las células Treg se caracterizan por la expresión constitutiva de CD25. Además, existen 
otros marcadores de superficie como GITR, CTLA-4, CD39 y CD73 y niveles altos del 
receptor de folato 4 (FR4), cuya presencia está relacionada con el desarrollo y función 
de las células Treg (22). Sin embargo, ninguno de estos marcadores es específico, dado 
que también se expresan en células T activadas, por lo que en estos momentos, la 
expresión del factor de transcripción FOXP3 constituye el marcador más específico 
para su identificación y estudio. 
 
3.3 Desarrollo de las células Treg  
Las Treg, al igual que todos los linfocitos T, derivan de las células progenitoras de la 
médula ósea y pueden desarrollarse tanto en el timo (células T reguladoras naturales; 
nTreg) como ser inducidas por otras células T de la periferia (células T reguladoras 
inducibles/adaptativas, iTreg) (Figura 1). Las nTreg provienen directamente de las células 
T precursoras CD4+ mediante un proceso de selección positiva a través de su 
interacción con el epitelio tímico y con las células dendríticas (DC) en presencia del 
complejo mayor de histocompatibilidad de clase II (MHC II) y del antígeno propio. Las 
 45 
 
Introducción 
 
células Treg, que constituyen de un 5-10% de los linfocitos CD4+ totales, pasan a 
continuación a la circulación periférica y se distribuyen tanto por los ganglios linfáticos 
como por el bazo (23), donde actúan sobre las células T autoreactivas que han 
escapado a la selección negativa del ti mo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 1. Desarrollo de las células Treg 
Los progenitores hematopoyéticos se generan en la médula ósea y posteriormente viajan al timo. En 
éste, las interacciones de alta afinidad tipo TCR-MHC II promueven la generación y expansión de las nTreg 
que serán liberadas a la circulación sanguínea. En la periferia, las iTreg se generan a partir de las células T 
CD4+ FOXP3- “naive” o vírgenes en presencia de citoquinas (TGF- e IL-2). Las células Treg suprimen la 
activación y proliferación de muchos tipos celulares, incluyendo las células TH1, TH2 y TH17. 
 
Las nTreg presentan un repertorio policlonal de receptores de células T (TCR), que les 
permite reconocer un amplio espectro de antígenos propios y no propios (24). 
En los últimos años se ha hecho evidente que las células Treg también podrían 
generarse directamente en la periferia bajo diferentes condiciones. El desarrollo “in 
vivo” de las células iTreg todavía no ha sido completamente esclarecido, sin embargo, 
se postula que estas células podrían derivar de linfocitos T “naive” o vírgenes como 
consecuencia de diferentes señales inductivas, como receptores de células T o 
citoquinas, o del factor de crecimiento transformante beta (TGF-β) o la IL-2 (Figura 1). 
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Bajo estas condiciones, las células iTreg madurarían en zonas periféricas, como por 
ejemplo en el tejido linfoide asociado a mucosas (MALT), donde adquirirían la 
expresión de los marcadores característicos de las células Treg anteriormente citados 
(CD25, CTLA4 y GITR). Después, tras la activación del factor de transcripción FOXP3, las 
células Treg comenzarían su efecto supresor. Esto incluiría la secreción de citoquinas (IL-
10 y TGF-β) tanto para detener el ciclo celular como para inducir apoptosis en las 
células T efectoras (TH1, TH2 y TH17), y el bloqueo de la co-estimulación y maduración de 
las DCs (25). Las células iTreg parecen ser esenciales en los procesos asociados a la 
tolerancia inmunológica en mucosas, en el control de la inflamación alérgica crónica 
severa y probablemente sean una de las principales defensas para la erradicación de 
los tumores (26). 
 
3.4 Función de los linfocitos Treg 
Las Treg FOXP3+ son capaces de suprimir, tanto de forma directa como indirecta, la 
activación y proliferación de muchos tipos celulares, siendo los más destacados los 
linfocitos T, B, las DCs y las células NK. 
Aunque se han propuesto diferentes mecanismos para explicar esta supresión, no ha 
sido posible clarificar hasta el momento todos los detalles implicados en este proceso. 
Diferentes hallazgos obtenidos mediante ensayos in vivo e in vitro indican que la 
supresión mediada por las células Treg podría ser realizada de varios mecanismos, 
independientes o dependiente de contacto (27) (Figura 2). 
Estudios recientes han descrito un mecanismo de supresión independiente de 
contacto, que utilizaría diferentes tipos de citoquinas, tales como la IL-10, IL-35 y TGF-
beta, como mediadores de dicha supresión (28). Según dichos estudios, tanto la IL-10 
como TGF-ß intervendrían dificultando la capacidad presentadora de antígeno 
mediante una inhibición del complejo mayor de histocompatibilidad de clase II y de las 
moléculas co-estimuladoras de las DCs, evitando así la maduración y activación de las 
DCs, tanto en humanos como en ratones (29) (Figura 2A). 
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Figura 2. Mecanismos básicos de supresión mediada por las células Treg 
A: Las células Treg secretan citoquinas supresoras que inhiben directamente las células T efectoras (Teff). 
B: Las células Treg FOXP3+ activadas pueden funcionar como células citotóxicas que expresan granzimas 
cuya función es colaborar en la eliminación de las células Teff. C: De igual forma, la molécula CD25 
(receptor alpha de la IL-2) tiene la capacidad de competir con células Teff por la IL-2, lo que dificulta la 
activación y expansión de las células T. Las células Treg también pueden inducir una señal inhibición a las 
células Teff a través de la regulación del AMP cíclico intracelular. D: Las moléculas CD80/CD68 presentes 
en la superficie de las APC interactúan con la molécula CTLA-4 de las células Treg, lo que deriva en la 
producción de IDO encargado de dirigir los efectos inmunodepresores.  
 
 
La actividad citosólica también ha sido propuesta como uno de los posibles 
mecanismos empleados por las Treg para suprimir la respuesta inmune. Después de su 
activación, las células Treg expresan granzimas responsables de la eliminación de los 
linfocitos CD4+ activados y linfocitos T CD8+ mediante un mecanismo dependiente de 
la perforina (30) (Figura 2B). 
Asimismo existe la posibilidad de que la falta de producción de IL-2 por parte de las 
células Treg FOXP3+, junto con una elevada expresión del receptor de IL-2 (IL-2R), haga 
Introducción 
 
 48 
 
Introducción 
 
que las Treg consuman la IL-2 presente en el entorno, lo cual puede contribuir a reducir 
la activación y expansión de las células Teff (31). 
Además de la supresión mediada por las Treg independiente de contacto, ha sido 
descrito otro mecanismo de supresión dependiente de contacto. En este caso, las 
células Treg envían una señal de tipo negativo a las células Teff a través del AMP cíclico 
intracelular, lo que conduce a la inhibición de la proliferación de las células T y a la 
producción de IL-2 (Figura 2C) (32). 
Las Treg también pueden entrar en contacto con las APC a través de la interacción 
CTLA4/CD80/CD86, lo que genera la inducción de un potente inmunosupresor, la 
enzima indolamina 2,3-dioxigenasa (IDO) (33) (Figura 2D). 
En resumen, los estudios realizados sugieren que existen múltiples mecanismos 
implicados en la supresión mediada por las células Treg y que existe una gran variedad 
de moléculas secretadas y/o expresadas en la superficie celular de las mismas que 
contribuyen directamente a sus funciones supresoras. 
El conocimiento de los mecanismos por los cuales las células Treg realizan su función 
constituye una extensa área de investigación con importantes implicaciones en el 
desarrollo futuro de estrategias terapéuticas para procesos patológicos como cáncer, 
diabetes y las enfermedades inmunológicas. 
 
3.5 Las células Treg y el cáncer 
El conocimiento de los mecanismos responsables de la tolerancia frente a los tumores 
es uno de los grandes desafíos de la investigación contra el cáncer. Cada vez resulta 
más claro que las células Treg desempeñan un papel activo y relevante en la progresión 
del cáncer y por tanto representan un factor importante en la supresión de la 
inmunidad específica del tumor (23, 34). 
En los últimos años, una serie de investigaciones han descrito la presencia de células 
inmunitarias específicas del tumor, tanto en neoplasias humanas como murinas (35). 
En estos casos, la presencia de células Treg en el microambiente tumoral podría inducir 
al “fallo” en el sistema inmunológico, lo que contribuiría al crecimiento y progresión 
del mismo. La presencia de un gran número de células Treg infiltrantes se ha asociado 
con una peor supervivencia y recidiva tumoral en cáncer de mama (36), ovario (37) y 
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gástrico (38). Además, se ha comprobado que la eliminación de las células Treg 
mediante la administración del anticuerpo monoclonal CD25 produce una mejora de la 
respuesta inmunológica frente los tumores y el desarrollo espontáneo de células Teff 
CD8+ y celulas NK (23). 
Para esclarecer el aumento del número de células Treg en los tumores se han propuesto 
varias hipótesis. Una posible explicación para explicar el reclutamiento de estas células 
sería la producción de la citoquina CCL22 por parte de las células tumorales y 
macrófagos infiltrantes, que atraerían a las células Treg CD25+ CD4+ CCR4+ (Figura 3).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 3. Supresión de la respuesta inmune tumoral mediada por las células Treg 
Tanto las células tumorales como los macrófagos asociados producirían la citoquina CCL22, responsable 
de la atracción de las células Treg a través del receptor CCR4 y por tanto de su acumulación en el 
microambiente del tumor (migración de Treg). Las células Treg entonces recibirían señales de proliferación 
(expansión de iTreg) a través de la presencia de antígenos propios asociados al tumor y de los altos 
niveles de TGF-β. Las DCs favorecerían aún más la expansión de células Treg. El gran número de células 
Treg presentes inhibiría a las células T natural killer (NTK), a los linfocitos T citotóxicos CD8+ (CTL) y a las 
células T CD4+ colaboradoras, lo que contribuiría a la progresión del tumor. (imagen modificada de 
Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer 2010. 127 (4):759-67) (41)). 
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El aumento de las células Treg en el microambiente tumoral podría ser debido a la gran 
proliferación y posterior muerte de las células tumorales, las cuales proporcionarían 
una gran cantidad de antígenos propios (39). Las células Treg FOXP3+ también  podrían 
originarse por la activación de células T CD4 “naive” o vírgenes tras las altas 
concentraciones de TGF-β secretado por las células tumorales o por las DCs presentes 
en el tumor (40). 
Por último, las células Treg podrían inhibir la actividad de células Teff, lo que daría lugar 
a una tolerancia frente al tumor (Figura 3). 
El efecto generado por las células Treg en la inmunidad tumoral en el caso de los 
linfomas es poco conocido. Estudios recientes sugieren que la composición celular del 
microambiente tumoral, en concreto la cantidad de Treg infiltrantes, pueden modificar 
de forma significativa la evolución clínica de las neoplasias hematológicas. Al contrario 
de lo observado en  tumores sólidos, en los linfomas de Hodgkin clásicos (cHL) (42) y 
foliculares (FL) (43) la presencia de un gran número de células Treg se correlaciona con 
una mejor respuesta terapéutica y una mayor supervivencia. Estos estudios sugieren 
que la presencia de células Treg en linfomas podría contribuir a la supresión, no sólo de 
las células citotóxicas infiltrantes, sino también de las propias células malignas. Por 
tanto, la implicación de las células Treg en estos tumores sería más compleja que en el 
caso de los tumores sólidos, por lo que se necesitan estudios adicionales. 
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4. Células T colaboradora del centro germinal (TFH) 
4.1 Las células TFH como un subtipo de células TH  
Las células TFH son células moduladoras esenciales para la respuesta inmune. A pesar 
de que carecen de la capacidad de atacar directamente a los patógenos invasores, son 
las responsables de coordinar la respuesta de otros muchos tipos celulares. 
Las células TFH son un subtipo de células T CD4+ que se localizan dentro de los folículos 
linfoides (área B) de los órganos linfoides secundarios (ganglios linfáticos, bazo y placas 
de Peyer). Los linfocitos TFH se caracterizan por la expresión del receptor CXCR5 (C-C 
chemokine receptor type 5), mediante el cual migran a los folículos linfoides de los 
tejidos anteriormente citados, donde colaboran en la diferenciación celular de los 
linfocitos B (9, 10). Estudios previos basados en análisis de perfiles de expresión génica 
han demostrado que las células TH que 
expresan altos niveles de CXCR5 presentan 
un perfil de expresión génica notablemente 
diferente de las células TH1, TH2, TH17 y de las 
células Treg, por lo que las células TFH forman 
una subpoblación de células T CD4+ (44, 45). 
A diferencia de otros subgrupos de células 
T, la transcripción génica de  las células TFH 
se caracteriza por la expresión de CD4, 
CD10, CXCR5, BCL6 (B-cell lymphoma 6), 
CD40L y CD57 (también presentes en las 
células B y en otros tipos de células T), así 
como por la expresión de otras moléculas 
cuya presencia parece ser más restrictiva de 
este tipo celular (Figura 1). Entre las 
moléculas relevantes para que las células 
TFH puedan desarrollar sus funciones de 
ayuda a las células B se encuentran ICOS 
(inducible T-cell co-estimulador), SAP 
(signaling lymphocytic activation molecule 
 
Figura 4. Interacción entre las células TFH y los 
linfocitosB 
Las interacciones entre las células TFH y las células B 
se encuentran mediadas por una serie de moléculas 
accesorias, como ICOS, PD1, CD40L y SAP en la 
célula TFH e ICOSL, PD1L, CD40 y la familia de 
receptores SLAM (CD84) en la célula B. Las células 
TFH también se caracterizan por la expresión de la 
proteína BCL6 y la producción de IL-21. 
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(SLAM)-associated protein) y PD-1 (programmed cell death 1) (Figura 4). Tanto el factor 
de transcripción BCL6 como la citoquina IL-21 tienen también un papel importante en 
la función y diferenciación de las células TFH, siendo considerados actualmente 
marcadores específicos de este tipo celular. 
 
4.2 El desarrollo de las células TFH 
El mecanismo de generación de las células TFH no se conoce con claridad en la 
actualidad. Una de las posibles hipótesis se encuentra ilustrada en la Figura 5. 
 
 
 
Figura 5. Generación de las células TFH 
En el área T de los órganos linfoides secundarios, las DCs activan a los linfocitos T CD4+ “naive” o 
vírgenes. Las señales de los receptores de las células T, junto con la co-estimulación proporcionada 
por las interacciones CD28/B7, CD40L/CD40, ICOS/ICOSL y PD1/PD1L son capaces de iniciar el 
programa de diferenciación de las células TFH. El aumento en la expresión de CXCR5 ayuda a las 
células TFH a localizar la región T-B, donde interactúan con las células B a través de las interacciones 
CD40L/CD40, ICOS/ICOSL, CD84/SAP y PD1/PD1L. Posteriormente, las células TFH  migran hacia el GC 
dónde colaboran en la diferenciación de los linfocitos B. 
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Una vez que las DCs reconocen al antígeno, éstas migran desde la periferia al área T de 
los tejidos linfoides, donde presentan al antígeno mediante el MHC II. Los linfocitos T 
CD4+ “naive” o vírgenes reconocen dicho antígeno mediante su receptor TCR 
específico, contactan con las DCs de forma estable y reciben señales de co-
estimulación debido las interacciones CD28/B7, CD40L/CD40, ICOS/ICOSL y PD1/PD1L y 
por la activación de BCL6 (46). Los linfocitos T ya activados, disminuyen la expresión 
del receptor CCR7 (chemokine (C-C motif) receptor 7) y aumentan la expresión de 
CXCR5. Como consecuencia, estos linfocitos migran hacia el folículo, en concreto al 
área T y B,  donde interaccionan con las células B para recibir una segunda cascada de 
señales de activación (25). 
La importancia de las células B en el desarrollo de las células TFH se basa en un estudio 
que ha demostrado que tanto la falta de células B como la ausencia de interacción B-
TFH, produce una ausencia de células TFH (47). Los contactos permanentes entre las 
células B y T se encuentran mediados por el receptor TCR y el MHC II. Una vez más, 
una amplia gama de receptores de superficie celular como CD40/CD40L, ICOS/ICOSL, 
miembros de la familia SLAM y PD1/PD-L1 son cruciales para completar y mantener la 
diferenciación de las células TFH (48). 
Estas interacciones culminan con la secreción por parte de las células TFH de citoquinas, 
en particular las IL-4 e IL-21, y la migración de las células TFH hacia el GC de los folículos 
(49). Aquellas células T activadas que no logran obtener las señales necesarias no 
entrarán en los GC. 
 
4.3 Las proteínas SAP y PD-1 en el desarrollo de células TFH 
Como ya ha sido mencionado, la familia de receptores de superficie SLAM juega un 
papel importante en la generación de las células TFH. La relevancia de estas moléculas 
en las interacciones T-B fue descubierta a raíz de los estudios con pacientes de XLP 
(enfermedad inmune linfoproliferativa ligada al cromosoma X). Esta inmunodeficiencia 
está causada por mutaciones en el gen que codifica para la proteína SAP (SH2D1A), 
molécula adaptadora citoplásmatica que interviene en la activación posterior de genes 
relacionados con la familia de receptores SLAM. Los pacientes con XLP, así como los 
ratones modificados genéticamente que carecen de expresión de la proteína SAP, 
exhiben una respuesta defectuosa de células B dependiente de células T (50, 51). 
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Estudios recientes han demostrado que la proteína SAP, que actúa después de CD84, 
es necesaria para regular la adhesión entre las células T y B. Por lo tanto, en ausencia 
de SAP o CD84, las células T CD4+ son incapaces de formar uniones permanentes con 
las células B, produciendo una disminución de las señales co-estimuladoras 
procedentes de las moléculas de superficie antes citadas y de las citoquinas que 
directamente influyen en la diferenciación y supervivencia de las células B (52). 
Otra molécula expresada por las células TFH es PD-1 (CD279). PD-1 y sus ligandos (PD-
L1 y PD-L2) juegan un papel importante en la inhibición de la regulación de la 
homeostasis inmune e intervienen en el mantenimiento de la tolerancia periférica 
(53). La evidencia de que PD-1 suprime la activación de la respuesta inmune proviene 
de estudios con ratones deficientes para esta proteína, los cuales desarrollan 
enfermedades autoinmunes espontáneas tales como el lupus eritematoso sistémico, 
miocardiopatía dilatada, artritis reumatoide o diabetes mellitus tipo I, debido a la 
activación persistente y descontrolada de las células T (54).  
Aunque la expresión de la proteína PD-1 es elevada en las células TFH, se sabe poco 
acerca del papel que juega en su desarrollo y función. Una posible función podría ser 
generar una señal inhibitoria sobre las células TFH, evitando la proliferación excesiva de 
células T CD4+ en el GC (55, 56). Por otro lado se postula que la inducción de PD-1 por 
las células TFH dentro del GC promueve la supervivencia y la selección de células B con 
receptores de inmunoglobulina de alta afinidad (57). 
 
4.4 Función de las células TFH 
Las células TFH se diferencian de otras subpoblaciones de células supresoras por su 
localización en los GCs de los órganos linfoides y por su capacidad para favorecer la 
activación, expansión y diferenciación de los linfocitos B y la formación del GC (58). 
El mecanismo de “ayuda” de las células TFH a las células B que se encuentra mejor 
caracterizado es el producido a través del ligando de CD40 (CD40L), cuya expresión en 
este tipo celular es muy alta. El CD40L es un activador muy potente de las células B, 
capaz de inducir proliferación celular. En combinación con determinadas citoquinas 
puede promover el cambio de isotipo y la diferenciación de las células B (59). La 
importancia de esta molécula en la respuesta de las células B ha sido demostrada en 
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modelos murinos que carecen de CD40 o CD40L, los quales presentan una disminución 
de la respuesta immunitaria y una incapacidad para generar GCs y células B de 
memoria (60). 
Otro mecanismo por el cual las células TFH regulan la respuesta de las células B es a 
través de la secreción de citoquinas. Las células TFH se caracterizan por la expresión de 
IL-21, citoquina capaz de modular la diferenciación y la proliferación de las células B 
(61). Recientemente se han identificado otra  serie de citoquinas (IL-4, IL-10, IL-17 e 
IFN-γ) secretadas por las células TFH y que juegan un papel importante en el cambio de 
isotipo y la producción de anticuerpos (62). 
 
4.5 Implicación de las células TFH en los linfomas 
Está aceptado de forma universal que las células TFH juegan un papel importante tanto 
en el microambiente del GC como en el desarrollo de las células B. Además, diferentes 
estudios han demostrado que las células TFH también pueden estar implicadas en 
enfermedades autoinmunes si se acumulan de forma aberrante o se desregulan (63). 
Estudios recientes sugieren que las células TFH pueden desempeñar un papel 
importante en la biología de los tumores y en particular, en las enfermedades 
linfoproliferativas (64). 
El microambiente del GC no es sólo un nicho esencial para la generación de la 
respuesta de las células B, sino que también se considera crítico para el desarrollo de la 
mayoría de las neoplasias linfoides humanas. Aunque la mayor parte de los linfomas 
que se originan de linfocitos del GC derivan de células B, se ha sugerido que algunos 
linfomas periféricos de células T, en concreto el angioimmunoblástico (AITL), podría 
tener su origen en las células TFH del GC. Esta hipótesis ha sido confirmada con 
estudios de perfiles de expresión génica llevados a cabo en linfomas periféricos de 
células T, los cuales han demostrado que la célula TFH representa la célula de origen del 
AILT, habiendo sido identificados PD-1 y CXCL13 como marcadores de esta 
subpoblación de células T (44).  
Otros estudios han puesto de manifiesto que los marcadores de TFH no son exclusivos 
del AITL, ya que también pueden estar presentes en otros tipos de linfoma de células 
T, concretamente en el linfoma cutáneo de célula T CD4+ pleomórfico de tamaño 
pequeño/mediano (CSTCL). Este hallazgo sugiere que no solo en el GC, sino también en 
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otras localizaciones podría tener lugar un proceso de estimulación de células B por 
parte de las TFH (65). 
En los últimos años, varios estudios han puesto de manifiesto la presencia de células 
TFH en una gran variedad de microambientes de linfomas B, destacando la importancia 
de la identificación de este tipo celular como una herramienta adicional para el 
diagnóstico de linfomas (64). Además, se ha comprobado que la presencia de TFH en el 
microambiente tumoral puede influir directamente en el desarrollo del tumor y podría 
ayudar a predecir tanto la respuesta a la terapia como la supervivencia (64). Un 
ejemplo lo constituye la presencia de células TFH en el linfoma de Hodgkin de 
predominio linfocítico (NLPHL), un tipo de linfoma de crecimiento lento caracterizado 
por la presencia de una pequeña población de células B neoplásicas dentro de un 
fondo enriquecido de linfocitos e histiocitos. La distribución de células TFH en este tipo 
de tumores no es aleatoria, ya que las células TFH PD-1 positivas forman rosetas 
alrededor de las células B neoplásicas, donde es probable que participen en el 
crecimiento y la supervivencia del tumor (66). 
El FL es una neoplasia derivada de los linfocitos B del GC, donde las células tumorales 
proliferan en los folículos en asociación estrecha con las células TFH y las DCs foliculares 
(67). Un estudio reciente ha demostrado que el número de células PD1 positivas que 
infiltran el tumor es un factor predictivo de supervivencia en pacientes con FL, lo que 
sugiere que PD-1 es capaz de identificar una subpoblación importante de TFH en el 
microambiente de este tipo de linfomas. Dicha subpoblación podría participar 
directamente en la modulación del comportamiento de las células tumorales y por 
tanto, influir en su evolución (68). 
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Objectives 
The overall goal of the present thesis is to study and characterize the Treg and TFH cell 
subtypes in reactive and lymphomas human tissues using two novel monoclonal 
antibodies against FOXP3 (Treg marker) and PD-1 (TFH marker). This work also analyses 
the possible diagnostic and prognostic value of FOXP3 and PD-1 mAbs in a survey of 
human lymphomas, focusing in particular on T-cell lymphomas.  
 
 
To achieve this overall goal we propose the following specific aims: 
 
First project 
 
o Production and characterisation of a novel FOXP3 mAb at single cell level. 
o To establish the predictive value of the detection of FOXP3 protein in routine 
paraffin tissue sections in a large set of lymphomas to evaluate its possible use 
as a diagnostic biomarker and its correlation with patient outcome. 
o To assess the presence of FOXP3+ T tumour-infiltrating cells in lymphomas and 
its correlation with patient outcome. 
 
Second Project 
 
o To study the distribution and phenotypic characteristics of PD-1 and SAP 
positive cells at single cell level by applying multi-immunolabelling techniques 
in lymphoid tissues.  
o To assess the diagnostic relevance of PD-1 and SAP protein in a set of human 
lymphomas focusing in particular on AITL and other subtypes of T-cell 
lymphomas.  
o To assess the diagnostic and prognostic potential of PD-1 as a marker of TFH 
cells present in the tumour microenvironment of nodular lymphocyte-
predominant Hodgkin lymphoma. 
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Materials and Methods 
1. Generation of FOXP3 and PD-1 monoclonal antibodies 
1.1. Antigen preparation 
1.1.1 Expression and purification of FOXP3 protein  
The cDNA clone containing the FOXP3 cDNA (IMAGE: 5747723) was obtained from the 
MRC geneservice. A cDNA fragment encoding the full-length human FOXP3 protein 
was amplified by PCR using the High Fidelity PCR system (Roche, Germany) and the 
primers: Forward 5’-GACAAGGATCCGATGCCCAACCCCAGGCC-3’ and reverse 5’-
CAGCAAAACGAGCTCTCAGGGGCCTCCC-3’, both primers contain BamHI and XhoI 
restriction sites, to facilitate directional cloning. The amplified product was inserted 
between BamHI and XhoI sites of the pENTR2B (Invitrogen, USA), using restriction 
enzyme digestion and ligase-mediated cloning. The resulting recombinant plasmid 
pENTR-FOXP3 was fully sequenced. Subsequently, the insert was transferred by means 
of Gateway technology into the E. coli destination vector pDEST15 (Invitrogen, USA) 
using the LR clonase enzyme mix (Invitrogen, USA), transformed into DH5α-competent 
cells and gene insertion was confirmed by PCR. The expression plasmid was named 
pDEST15-FOXP3 and was used to transform BL21 (DE3) pLysS competent cells 
(Novagen, Germany). A single colony was grown overnight at 37ºC in LB medium 
supplemented with 100 μg/ml ampicillin and 35 μg/ml chroramphenicol. After 
overnight growth, the cells were diluted 100-fold in fresh medium and grown at 37ºC 
to mid-log phase (A600= 0.5-0.7), where induction was initiated by the addition of 0.4 
mM IPTG (Roche, Germany). After 3 h induction, cells were harvested by centrifugation 
and resuspended in 0.02 culture volumes of PBS. Three freeze-thaw cycles followed by 
sonication (three bursts of 30 seconds each) on ice were used to disrupt the cells and 
the soluble and insoluble fractions were separated by centrifugation. The levels of 
expression and solubility were analysed using Coomassie-stained SDS-PAGE and 
immunoblotting as described below. 
Recombinant GST-FOXP3 contained in the soluble fraction of induced cells was purified 
by affinity chromatography using a GSTrap column (GE Healthcare, USA) on an ÄKTA 
Prime (GE Healthcare, USA). The binding buffer was 20 mM sodium phosphate pH 7.3 
with 0.15 M NaCl and the elution buffer was 50 mM Tris-HCl pH 8.0 with 10 mM 
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reduced glutathione. After elution by means of a step gradient from 0% to 100% of 
elution buffer, fractions were monitored at 280 nm and those containing GST-FOXP3 
were pooled and dialyzed against PBS. 
 
1.1.2 YT cell line was used as immunogen for the production of PD-1 
monoclonal antibody  
A human T/NK cell line called YT (DSMZ, Germany), expressing high level of PD-1 
protein, was used as a source of antigen. All cells were cultured in RPMI medium 
(Gibco, Germany) containing 10% fetal calf serum (FCS) (Gibco, Germany), 4 mM 
glutamine, 10 U/ml penicillin and 100 µg/ml streptomycin (Boehringer, Germany). 
 
1.2. Immunization 
Two female Balb/c mice were immunized intraperitoneally (i.p.) with 100ug of purified 
GST-FOXP3 protein in phosphate-buffered saline (PBS) with 1:1 complete Freund’s 
adjuvant (Chemicon, USA). For the production of PD-1 antibody two female Balb/c 
mice were immunized i.p. with 2x106 YT cells in PBS without Freund’s adjuvant. At day 
14, the mice were injected i.p. with additional 100 µg of purified GST-FOXP3 without 
Freund’s adjuvant (Chemicon, USA) and with 2x106 YT cells respectively. At Day 28, the 
mice were injected i.p. with an additional boost of 150ug of purified GST-FOXP3 
protein and in case of PD-1 mice with a boost of 2x106 YT cells. Mice were bled for 
serum titers determination on day 38. In case of FOXP3, mice received a final boost of 
150ug of GST-FOXP3 protein in PBS, i.p., 3 days prior to fusion. In case of PD-1, mice 
received a final boost of 2x106 YT cells i.p. 
 
1.3 Fusion procedure 
1.3.1. Culture myeloma cells 
One week before fusion, we proceed to the expansion of NS1/Ag4-1 (NS-1) myeloma 
cell line (the fusion partner cell line). NS-1 cell line was cultured in RPMI medium 
(Sigma-Aldrich, USA) containing 10% FCS (Gibco, Germany), 4 mM glutamine, 10 U/ml 
penicillin and 100 µg/ml streptomycin (Boehringer, Germany). One day before the 
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fusion, we moved the cells into fresh medium with a final concentration of 5x105 
cells/ml. The cell viability at the time of cell fusion was greater than 95%. 
 
1.3.2 Standard fusion procedure 
Three days after the final booster the mouse was sacrificed. We aseptically removed 
the spleen from the selected mouse, we placed it in a 60-mm-diameter Petri dish with 
5 ml of complete medium (RPMI medium containing 10% of FCS, 4 mM glutamine, 10 
U/ml penicillin and 100 µg/ml streptomycin), and we carefully teased it apart. The cell 
suspension was then transferred to 10ml falcon tube. The spleen cells were 
centrifuged (1000rpm for 10 min) and the cell pellet was resuspended with 5 ml of 
RPMI medium without serum. At the same time the NS-1 myeloma cell line was 
washed with 5ml of RPMI medium without serum and centrifuged (1000rpm for 10 
min). Both cell pellets were resuspended in a pre warmed medium without serum and 
combined. The cell suspension was centrifuged (1000rpm for 5 min) and the medium 
was then carefully removed. The pellet was disaggregated by gently tapping the 
bottom of the tube. 1.2 ml of warmed (37°C) 50% polyethylene glycol 1500 (Roche, 
USA) was slowly added, drop by drop, for 1 minute with gentle mixing. 2 and 4 mls of 
warm (37oC) medium without FCS were added over a period of 2 and 4 minutes, again 
gently swirling the tube. A final volume of 8ml of medium with 10% FCS was finally 
added. The cells suspension was then centrifuged (1000rpm for 5 min). 
The cell pellet was carefully resuspended in 350 ml of complete RPMI media and 
plated in 14 plates (24-well tissue culture plates) (Thermo Fisher, USA). The plates 
were then placed in a 5% CO2/air incubator at 37°C. The day after, 1 ml of complete 
media with 2xHAT (hypoxanthine, aminopterin and tymidine) (Gibco, Germany) was 
added in each well. Clones were visible by microscopy at about day four and by eye 
starting at day 7. After 10 days the plates were inspected for growth and supernatants 
were collected for ELISA testing. 
 
1.3.3 Single-cell cloning by limiting dilution 
Because more than one hybridoma colony might be growing in the same plate well, 
cells that give a positive result in the screening assays must be isolated. A general 
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procedure for cloning individual hybridomas consists in the single cell cloning 
technique. 
The hybridoma cells were healthy and rapidly growing at the time of cloning. A tube 
with 10 ml of supplemented medium (RPMI medium containing 10%  FCS, 4 mM 
glutamine, 10 U/ml penicillin, 100µg/ml streptomycin and 2% condimed (Roche, USA) 
was prepared. 10 μl media containing hybridoma cellsfrom the hybridoma flask was 
added to the 10 ml tube. After counting the cells present in the 10 ml tube, we worked 
out the volume of medium that was containing 96 cells. The correct volume was added 
in 16 ml of supplemented medium and, using a multiwell pipettor (Thermo Fisher, 
USA), 200 μl of the 16ml medium was added in a 98 well culture plate. The 98 well 
plates were then placed in a 5% CO2/air incubator at 37°C. Clones appeared in around 
7 days and they were ready to be screened after 10 days. Supernatant coming from 
the wells containing a single colony were tested by ELISA or imminohistochemisty in 
tranfected cells. The clones that secrete the desired antibody were expanded and 
several aliquots of them were frozen before proceeding to large-scale antibody 
production. 
 
2. ELISA (enzyme-linked immuno-absorbant assay) 
ELISA testing was performed to screen fusion supernatant since is the most suitable 
screening assay for soluble antigen. Ninety-six-well microtiter plates (Nunc, Denmark) 
were coated for 1 hr at 37ºC with 50μl/well of the proper antigen (diluted 5μg/ml in 
distilled water). The plates were then washed three times with PBS/Tween and 200 
μl/well of PBS plus 2% of dry milk powder was added.  The plates were left overnight in 
a cold room. One day after the plates were washed 3 times in PBS/Tween and 50μl of 
each supernatant that you wished to test were added to the plates and incubated for 1 
hr at 37ºC. We also added to the ELISA plate the mouse serum coming from the same 
mouse, diluted 1:100 and 1:200 in PBS as a positive control. The negative control used 
was the PBS alone. The plates were then washed three times with PBS/Tween and 
three times with distilled water. 100 μl of substrate buffer (Roche ABTS Solution, USA) 
were then added. After around 15 minutes the positives clones were visible and 
selected. 
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3. Eukaryotic expression of proteins in COS-1 and HEK293T cells 
To confirm that our mAbs were specifically reactive with the FOXP3 protein (Forkhead 
box protein P3 (NP-054728.2)), their reactivity was tested on COS-1 cells (fibroblast-
like cell line derived from monkey kidney tissue, ATCC, USA) expressing FOXP3 and on 
COS-1 cells expressing the closely related FOXP1, FOXP2 and FOXP4 proteins. The Flag-
tagged FOXP3 cDNA was kindly provided by Dr Mary Brunkow, Celltech. 
On the other and to confirm that the monoclonal antibody NAT recognized human PD-
1 protein (Homo sapiens programmed cell death 1 (NP_005009.2)), a pCMV6-XL5-PD-1 
vector (Origene, USA) expressing human PD-1 was transfected into HEK293T cells 
(Human embryonal kidney cell line, ATCC, USA).  
Plasmid DNAs were prepared for transfection using the Plasmid Midi Kit according to 
the manufacturer's instructions (Genomed, Germany). COS-1 cells were respectively 
transfected with pcDNA4/HisMax/ FOXP2, FOXP3, pcDNA4/HisMax/FOXP4, 
pcDNA4/HisMax (kindly provided by Dr Mary Brunkow, Celltech) alone or pAB195 
(FOXP1) using Fugene 6 transfection reagent, following the protocol described by the 
manufacturer (Roche, USA). The HEK293T cells were tranfected with a pCMV6-XL5-PD-
1 vector using the same protocol used for FOXP family vectors. 
Cell pellets were snap-frozen and stored at -70oC whereas cytocentrifuge preparations 
were made for immunocytochemical staining and stored at -20ºC. Paraffin-embedded 
cell pellets were prepared by fixing transfectants for 48 h in neutral buffered formalin 
(10% formalin in PBS), before centrifugation into 2% agar in neutral buffered formalin; 
the agar pellet was then embedded in paraffin and sectioned as for tissues.  
 
4. Immunohistochemistry in cytospin of trasfected COS-1 or HEK293T 
cells 
Since screening for the presence of specific antibodies by ELISA may not able to detect 
antibodies that recognize conformational epitopes of interest we also performed a 
secondary screening technique on the positive clones selected by ELISA. 
Immuhohistochemistry in transfected COS-1 and HEK293T cell expressing the protein 
of interest was performed as follow:  A suspension of COS-1 or HEK293T tranfected 
cells containing 0.5x106 cells/ml was prepared. We assembled the cytospin slide holder  
 
 65 
 
Materials and Methods 
(Thermo Fisher, USA) using an ethanol-cleaned slide and a cytospin filter. We 
transferred 80 to 150 µl of cell suspension into the cytospin chamber and centrifuge 
(1000rpm for 5 min) at room temperature. The slides obtained were dried 24 hr at 
room temperature. Cytospin preparation were incubated with 100μl the supernatnat 
for 30 min at room temperature. The slides were then incubated with HRPconjugated 
goat anti-mouse-Ig (diluted 1:100 in PBS) (Dako, Denmark). The peroxidase reaction 
was developed using 3, 3'-Diaminobenzidine (DAB) (Dako, Denmark) for 5 min and 
washed with distilled water.  
 
5. Antibodies  
The antibodies used in the thesis are summarized in the Table 1. 
Table 1. Antibodies used in FOXP3 and PD-1 study 
Anti-  Clone  name Source 
BCL6  GI191E/A8  CNIO Monoclonal Antibody Unit, Madrid, Spain 
CD3 A0452 Dako, Glostrup, Denmark 
CD4 MT310 Dako, Glostrup, Denmark 
CD8 C8/144B Dako, Glostrup, Denmark 
CD10 NCL-L-CD10-270 Novocastra Laboratories, Newcastle, UK 
CD20 L26 Dako, Glostrup, Denmark 
CD25 4C9 Novocastra, Newcastle upon Tyne, UK 
CD57 B321 (NK-1) Abcam, Cambridge, UK 
CXCL13 53610 R&D Systems, Minneapolis, USA 
PD-1  NAT CNIO Monoclonal Antibody Unit, Madrid, Spain 
FLAG F3165 Sigma-Aldrich, USA 
FOXP1 JC12 Abcam, Cambridge, UK 
FOXP3  Goat polyclonal Abcam, Cambridge, UK 
GAPDH FF26 CNIO Monoclonal Antibody Unit, Madrid, Spain 
SAP  FL-128 Santa Cruz Biotechnology, Ca, USA 
Xpress R910-25 Invitrogen, Oregon, USA 
 
6. Patient samples 
6.1 Patient samples used in the FOXP3 project 
Lymph node biopsies from 23 patients with adult T-cell leukaemia/lymphoma (ATLL) 
were provided by Dr K Ohshima from the Department of Pathology, School of 
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Medicine, Fukuoka University, Fukuoka, Japan and two cases where obtained from the 
tissue archives of the CNIO Tumour Bank. HTLV-1 provirus integration was confirmed 
in all ATLL samples by ELISA and Southern-blot techniques. 
A large series of samples representing T- and B-cell neoplasms, including T-cell 
lymphoblastic lymphoma (4), peripheral T-cell lymphoma (20), angioimmunoblastic T-
cell lymphoma (5), T cell/natural killer cell lymphoma (5), anaplastic large cell 
lymphoma (9), mycosis fungoides (15), B-cell lymphocytic leukaemia/lymphoma (14), 
mantle cell lymphoma (14), marginal zone B-cell lymphoma (12), diffuse large B-cell 
lymphoma (17), follicular lymphoma (17) and Burkitt’s lymphoma (15) were used in 
this study. Informed consent was obtained from all patients included in the study 
under the supervision of the local ethical committees. Reactive (non-neoplastic) 
lymphoid tissues (five tonsillectomy specimens, five lymph nodes, five spleens and five 
thymus) were obtained from the CNIO Tumour Bank. Frozen sections of spleen and 
lymph node were also obtained from normal mice (Balb/c or B6 strains). 
 
6.2 Patient samples used in the PD-1 project 
Biopsy samples (fresh and formalin-fixed paraffin-embedded tissues) were obtained 
from the tissue archives of the CNIO Tumor Bank, from the files of the Histopathology 
Department ,John Radcliffe Hospital, from the Institute of Pathology, University of Kiel 
and from the Department of Pathology, University Clinic, Frankfurt. The material 
investigated comprised sections of either whole tissue blocks or tissue-arrays, 
prepared as illustrated above. The diagnosis of angioimmunoblastic T cell lymphoma 
was based on a combination of morphologic features (e.g. "clear cell" neoplastic cell 
morphology, expanded follicular dendritic cell meshworks and vascular proliferation) 
and phenotype (e.g. expression by tumor cells of CD3 and CD4 accompanied by CD10 
and/or BCL6). 
One hundred fifty-two cases previously diagnosed as nodular sclerosis Hodgkin 
lymphoma (NSHL), mixed cellularity classical Hodgkin lymphoma (MCHL), lymphocyte-
rich classical Hodgkin lymphoma (LRCHL), nodular lymphocyte-predominant Hodgkin 
lymphoma (NLPHL) and T cell /histiocyte-rich B cell lymphoma (T/HRBCL) were 
obtained from the files of the Molecular Pathology Programme of the CNIO. The cases 
were classified into 7 diagnostic groups: NSHL (n=43), MCHL (n=14), LRCHL (n=13), 
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NLPHL (n=58), NLPHL with diffuse areas (n=7), T/HRBCL (n=12) and NLPHL versus 
T/HRBCL (n=5). Briefly, NLPHL tumors were considered to be those with scattered 
CD30-negative tumoral cells within follicular dendritic cell meshworks accompanied by 
follicular T-cell rosettes surrounding the tumoral cells. Cases featuring diffuse areas 
with frequent tumoral cells, lacking follicular dendritic cell meshworks, in association 
with typical nodular zones of NLPHL, were classified as NLPHL with diffuse areas. 
T/HRBCL cases were characterized by diffuse areas with scattered CD20-positive 
tumoral cells, surrounded by numerous T cells and histiocytes without follicular 
dendritic cell meshworks. Five cases could not be classified either as NLPHL, NLPHL 
with diffuse areas, or T/HRBC and so were assigned to a separate group named as 
NLPHL versus T/HRBCL. All samples were reviewed by at least two pathologists, and in 
each case diagnosis had been made on the basis of conventional histologic and 
immunohistologic examination according to the criteria of the World Health 
Organization (WHO) classification (1). 
 
7. Tissue microarrays preparation 
Tissue microarrays (TMA) were built using tissue cores from formalin-fixed paraffin 
embedded tumours. Hematoxylin and eosin (H&E) stained slides were reviewed, and 
areas containing tumour tissue were marked on both the slides and corresponding 
paraffin blocks for tissue microarray construction. Microarray blocks were constructed 
using a manual arrayer (Beecher Instruments, USA) as previously described (69). Briefly, 
the instrument was used to create holes in a recipient block with defined array 
coordinates. A solid stylet was used to transfer the tissue cores into the recipient block. 
Two 0.6-mm-diameter tissue cores were taken from each case. Several composite 
high-density TMA blocks were designed, and serial 4-μm sections were cut with a 
microtome (Leica, Germany) and transferred to poly-l-lysine coated slides (Thermo 
Fisher, USA). One section from each tissue array block was stained with H&E. The 
remaining sections were stored at room temperature. 
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8. Immunohistochenistry  
8.1 Immunohistochemistry in frozen tissue sections 
Frozen tonsil tissue sections were incubated for 30 min with primary Ab, washed in 
PBS and incubated with either HRPconjugated goat anti-mouse-Ig (diluted 1:100 in 
PBS)(Dako, Denmark) or HRP conjugated rabbit anti-goat-Ig (diluted 1:100 in PBS)(Dako, 
Denmark). The peroxidase reaction was developed using DAB (Dako, Denmark) for 5 
min and washed with distilled water. Murine tissue sections were fixed in acetone, 
blocked with 10% normal FCS, incubated with each mAb followed by anti-mouse-
Texas-red (diluted 1:100)(BD Bioscience, USA) and anti-CD4-FITC (diluted 1:75) (BD 
Bioscience, USA). 
 
8.2 Immunohistochemistry in paraffin tissue sections 
Immunohistochemistry on paraffin sections was performed using the pressure-cooking 
method of antigen retrieval (2 min, citrate pH 6.5 or Tris-EDTA buffer). Before staining, 
endogenous peroxidase was blocked; the slides were incubated for 40 min with the 
primary antibody and washed with PBS. Immunodetection was performed with 
biotinylated anti-mouse secondary antibodies (25 min), followed by peroxidase-
labelled streptavidin (LSAB- Dako, Denmark) (25 min) and DAB chromogen as substrate. 
All immunostaining was performed using the Techmate 500 automatic immunostaining 
device and reagents supplied by DakoCytomation (Dako, Denmark). 
 
8.3. Double immunoenzymatic staining 
In the first reaction, immunostaining was performed using the EnVision peroxidase kit 
and diaminobenzidine (DAB) chromogen-substrate (Dako K5507, Dako, Denmark). In 
the second reaction, immunostaining was performed using the alkaline phosphatase 
kit (Dako K5355, Dako, Denmark) and the chromogen provided with the kit 
manufacture instruction. 
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9. Immunofluorescence 
Double immunostaining was performed by incubating paraffin sections following 
antigen retrieval for one hour at room temperature in a humid chamber with a mixture 
of the two primary antibodies diluted in PBS + 10% FCS (Life Technologies, USA). Slides 
were then washed three times in PBS containing 0.5% Tween 20 for periods of 5 
minutes. Slides were subsequently incubated for one hour with fluorochrome-
conjugated antibodies specific for different Ig isotypes (Molecular Probes, The 
Netherlands) (diluted in PBS 1:200) in a humid chamber in the dark. Slides were 
washed three times subsequently in PBS containing 0.5% Tween 20 for 5 minute 
periods. Following washing, sections were mounted in antifading mounting medium 
(Qbiogene, France) containing DAPI (Molecular Probes, The Netherlands). Slides were 
examined on a Nikon E800 Eclipse fluorescence microscope (Nikon, Kingston-upon-
Thames, UK) equipped for epifluorescence, and images were captured with an 
Axiocam chargecoupled device (CCD) camera (Zeiss, Germany) and Axiovision software 
(Imaging Associates, UK), and adjusted using Photoshop software (Adobe, San Jose, 
USA). 
 
10. Immunoperoxidase staining, combined with single or double 
immunofluorescence 
Slides were immunostained for corresponding antibody by the two-stage peroxidase-
based EnVision technique, washed in PBS for up to 5 minutes. Haematoxylin staining 
was omitted .The slides were then incubated in FCS for up to 10 and incubated for 45 
minutes at room temperature with a the corrisponding antibodies that were either 
from different species or of differing immunoglobulin isotype/subclass. Sections were 
washed in PBS for up to 5 minutes and then incubated in the dark for 45 minutes with 
secondary antibodies (specific for species, isotypes, or subclass) and labelled with 
contrasting green and red fluorochromes (Alexa Fluor 488 and Alexa Fluor 594, dilution 
1:100) (Molecular Probes, The Netherlands). The slides were washed in PBS for up to 5 
minutes, mounted in fluorescent mounting medium (Dako, Denmark) containing 1 
µg/ml DAPI (4,6-diamidino-2-phenyllindole). 
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Slides were examined on a Nikon E800 Eclipse fluorescence microscope (Nikon, UK) 
equipped for epifluorescence, and images were captured with an Axiocam 
chargecoupled device (CCD) camera (Zeiss, Germany) and Axiovision software (Imaging 
Associates, UK), and adjusted using Photoshop software (Adobe, USA). 
 
11. Western Blotting 
To extract total protein, cells were lysed in a buffer containing 50 mM Tris (tris 
(hydroxymethyl) aminomethane)-HCl, pH 7.5, 150 mM NaCl, 1% Igepal (Sigma, USA) 
and protease inhibitors (Roche, Germany). Lysates were incubated in a cool room on a 
rotary shaker for 1 hour and cleared by centrifugation.  
The total lysates of each cell line were denatured by heating in Laemmli sample buffer, 
resolved in a 10% sodium dodecyl sulfate–polyacrylamide gel (SDS-PAGE) and 
transferred onto nitrocellulose membranes for 2 hours. Membranes were incubated 
overnight with blocking solution (5% milk in PBS) and immunoblotted for 1 hour at 
room temperature with the corresponding antibody (neat supernatant) and GAPDH 
monoclonal antibody (1:10) (CNIO, Spain), followed by incubation with horseradish 
peroxidase-conjugated secondary antibody (1:1000) (DAKO, Denmark). Finally, the 
blots were visualized using the ECL detection system (Amersham Biosciences, UK) in 
accordance with the supplier’s instructions. 
 
12. T cell clones and activation 
The CD8+ clones, 2D10 and 3F6, were generated by tetramer staining and FACS cloning 
and maintained as described previously (70). The CD4+ clone TB1 generated from a 
patient with a thymoma, as described previously (71), was kindly provided by 
Professor Nick Willcox (Oxford, UK). The cells were maintained in culture in RPMI-1640 
containing 10% fetal calf serum at 37ºC in 5%CO2. Cells were activated, within 10–14 
days, by stimulation with 20 lg/ ml phytohemagglutinin (Sigma-Aldrich, USA) and 
irradiated allogeneic peripheral blood lymphocytes (50 Gy). Cells were considered to 
be resting after more than 21 days post-stimulation. 
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13. Cell isolation and immunofluorescent labeling of sorted cells 
Human mononuclear cells were isolated from fresh blood by Lymphoprep (Nycomed, 
Oslo) gradient centrifugation. The CD4+ cells were obtained by negatively sorting the 
mononuclear cells with CD8 and CD14 magnetic beads (Miltenyi Biotech, Germany). 
These were then positively sorted for CD4+CD25+ cells using CD25 magnetic beads 
(Miltenyi Biotec, Germany). In some instances, CD4+CD25+ cells were isolated using 
the CD4+CD25+ regulatory isolation kit according to the manufacturer's instructions 
(Miltenyi Biotech, Germany). MACS-sorted CD4+CD25+ and CD4+CD25– cells isolated 
from human peripheral blood were spotted onto slides at 5 x 104/spot. Slides were air-
dried and then frozen at -20ºC. Cells were fixed in pre-chilled acetone (-20ºC) for 5 min 
and blocked with 10% normal goat serum. Primary Ab (clone 221D/D3) was added 
overnight at 4ºC, followed by goat anti-mouse-AlexaFluor-488 (1:500) (Molecular 
Probes, The Netherlands). Cytocentrifuge preparations of T cells purified for the 
suppression assay were air-dried overnight, fixed in 50:50 acetone: methanol for 60 
sec at room temperature, rinsed in PBS, then incubated with primary mAb (clone 
236A/E7) for 50 min. Following a 5-min wash in PBS the secondary Ab (goat anti-
mouse-IgG1-AlexaFluor-546, Molecular Probes) diluted 1:400, was applied for 30 min. 
 
14. FACS staining of FOXP3-transfected COS-1 cells 
COS-1 cells were permeabilised with FACS Perm 2 solution (BD Biosciences, USA). Cells 
were stained with each FOXP3 mAb and wiyh a secondary goat-anti-mouse-PE 
(Southern Biotech, USA). They were analyzed using FACS Calibur (BD Biosciences, USA) 
and CELLQuest software. 
 
15. FACS methodology for detecting endogenous FOXP3 
For FACS analysis, 5 x 105 cells were fixed in 1 ml of PBS with1% paraformaldehyde and 
0.05% Tween-20 overnight at 4ºC. Cells were treated twice with 0.5 ml of DNAse at 
100 Kunitz/ml according to the manufacturer's instructions (Sigma-Aldrich, USA). 
Staining steps were performed at room temperature for one hour. Cells were 
incubated with mouse anti-human-FOXP3 (clone150D/E4), washed with FACS buffer 
(PBS, 3.00% fetal calf serum, 0.50% Tween-20 and 0.05% azide). FOXP3 Ab binding was 
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detected using Alexa Fluor-488J goat anti-mouse-IgG (Molecular Probes, USA) and 
washed as above. Cell surface staining was then performed using the mAb Cy-Chrome-
anti-human-CD4 (Pharmingen) and PE-anti-human-CD25 (Miltenyi Biotec, Germany) 
for 20 min at room temperature followed by washing in PBS/BSA. Cells were analyzed 
using a FACSCaliburTM with CELLQuestTM software (Becton Dickinson, USA) 
 
16. Cell proliferation assay 
Cells were cultured in RPMI-1640 medium (Sigma, USA) supplemented with 5% human 
AB serum, 2 mM L-glutamine (Gibco/Invitrogen, USA), 100 U/lg/ml 
penicillin/streptomycin (Gibco/Invitrogen, USA), 0.5 mM sodium pyruvate 
(Gibco/Invitrogen, USA) and 0.05 mM nonessential amino acids (Gibco/Invitrogen, 
USA) in 96-well plates (NalgeNunc, USA). Plate-bound anti-CD3 (clone UCHT1) and 
soluble anti-CD28 (clone 28.2) were purchased from Pharmingen (BD Biosciences 
Pharmingen). The CD4+CD25- responder cells were used at 5 x 104/well and a variable 
number of CD4+CD25+ regulatory cells were added. 3H-thymidine at 0.5 µlCi per well 
was added for the final 16 h of a 5-day assay. 
 
17. Statistical analysis 
Overall survival (OS) was calculated from the date of pathological diagnosis to death or 
to the last date of follow up. Actuarial survival curves, in terms of OS, were estimated 
by the Kaplan-Meier method and statistical significance of difference between FOXP3-
positive and -negative cases were evaluated using the log-rank test. Median OS was 
also compared with a one-factor ANOVA method. A P-value of 0.05 or less was 
considered statistically significant. The SPSS software package (SPSS Inc., Chicago, IL; 
1999) was used for the analyses. 
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1. First project: Regulatory T cells 
1.1 The Abcam goat polyclonal FOXP3 Ab labels the human FOXP3 protein 
in frozen but not routinely fixed tissues 
The commercially available Abcam goat polyclonal FOXP3 Ab was evaluated as a 
reagent to detect the FOXP3 protein in human tissues. Immunohistochemistry 
confirmed that the Ab recognized the human flag tagged FOXP3 protein expressed in 
COS-1 cell transfectants and stained scattered interfollicular cells in tonsil (Figure 1). 
However, we were unable to detect the FOXP3 protein in routinely fixed paraffin-
embedded tissues with this reagent and thus additional reagents were necessary to 
investigate archival biopsy material. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Immunolabeling of tonsil and FOXP transfectants. The top and 
middle rows show immunoperoxidase labeling with the commercial goat 
polyclonal Ab or the 236A/E7 mouse FOXP3 mAb, respectively, on tonsil 
and FOXP3-COS-1 transfectants. The bottom row shows the lack of staining 
with the 236A/E7 FOXP3 mAb on COS-1 cells transfected with the related 
FOXP proteins. The insets at top right of the bottom row confirm the 
expression of these recombinant FOXP proteins using the indicated Ab. 
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1.2 Generation of novel FOXP3 mAbs  
The hybridoma fusion generated seven FOXP3 mAbs (86D/D6, 150D/E4, 157B/F4, 
206D/B1, 221D/D3, 236A,E7 and 259D/C7) that showed a similar staining pattern, of 
scattered inter follicular cells on frozen tonsil, to that observed with the polyclonal 
FOXP3 Ab (Figure 1). We observed more FOXP3+ cells using our FOXP3 mAbs, which 
showed a stronger reactivity than was obtained with the polyclonal Ab. The reactivity 
of these FOXP3 mAbs was further investigated. 
 
1.3 The mAbs specifically recognize FOXP3 and not other FOXP proteins 
To confirm that the new mAbs recognized the human FOXP3 protein, expressed in 
COS-1 cells, was tested by immunohistochemistry on frozen cytospin preparations. 
Labeling with the anti-FLAG mAb confirmed the efficiency of transfection and the 
subcellular distribution of the recombinant FOXP3 protein. Cytoplasmic expression of 
proteins that are normally nuclear is commonly observed when cells are transfected 
using the described Fugene protocol and harvested after 24 h. All of the 7 mAbs 
specifically recognized the human FOXP3 protein by immunohistochemistry. There is 
significant sequence similarity between the four members of the FOXP family, FOXP1–
4, particularly within the DNA binding forkhead domain. As a full-length FOXP3 protein 
was used as an antigen it was important to ensure the specificity of the mAbs for 
FOXP3 and exclude the possibility of their cross-reactivity with other FOXP proteins. 
Expression of the FOXP1, FOXP2 and FOXP4 proteins in transfected cells was confirmed 
using the JC12 mAb to label FOXP1 and the anti-Xpress antibody to detect epitope-
tagged FOXP2 and FOXP4 (Figure 1). All the FOXP3 mAbs specifically labeled the COS-1 
cells expressing FOXP3 and not those expressing the other FOXP proteins. 
We have investigated a FOXP3 murine mAb, hFOXY (Cat No 14-5779, eBioscience, USA) 
that is commercially available and compared its reactivity on tonsil with that obtained 
with our 236A/E7 FOXP3 mAb (data not shown). On frozen tonsil sections hFOXY 
stained scattered interfollicular cells at a dilution of 1:25. At this dilution some 
background staining was observed and there was a noticeably smaller population of 
nuclear positive cells than was stained with our FOXP3 mAb 236A/E7. Staining of COS-1 
cell transfectants confirmed that hFOXY detected the FOXP3 protein and not the 
related FOXP1, FOXP2 or FOXP4 proteins. Staining of paraffin-embedded COS-1 cell 
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transfectants indicated that hFOXY recognizes a formalin-resistant epitope on FOXP3 
and no cross-reactivity was observed under these conditions with other FOXP proteins. 
Thus hFOXY is suitable for detecting FOXP3 by immunohistochemistry on both frozen 
and paraffin-embedded tissues. However, this reagent may only detect a 
subpopulation of FOXP3+ cells. 
 
1.4 The FOXP3 mAbs recognize the FOXP3 protein in a variety of 
applications and two are cross-reactive with the murine Foxp3 protein 
The FOXP3 mAbs were tested for their ability to recognize formalin-resistant epitopes 
by immunohistochemistry using routinely fixed tonsil and formalin-fixed paraffin-
embedded pellets of FOXP3-transfected COS-1 cells. All of the mAbs recognized the 
FOXP3 protein in routinely fixed tissues and labeled FOXP3 transfectants. Some mAbs 
gave less non-specific background staining than others, whereas some showed 
stronger labeling of positive cells, these data are summarized in Table 2. Abs 86D/D6 
and 236A/E7 are recommended for immunohistochemistry on paraffin-embedded 
tissues. 
 
Table 2. Reactivity of FOXP3 mAbs 
 
 
 
 
 
 
 
The ability of the mAbs to recognize the FOXP3 protein by flow-cytometry and by 
Western blotting was also tested using FOXP3-transfected COS-1 cells. All the mAbs 
recognized the recombinant FOXP3 protein to some extent in Western blotting and in 
flow cytometry (Table 2). The human and murine FOXP3 proteins are approximately 
87% identical, thus the FOXP3 mAbs were also tested for reactivity with the murine 
Foxp3 protein. The mAbs 150D/E4 and 221D/D3 were found to be cross-reactive with 
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the murine Foxp3 protein and specifically labeled CD4+ T cells in murine spleen and 
lymph nodes (data not shown as these are consistent with the human data). 
1.5 Characterization of FOXP3 protein expression in normal human tissues 
FOXP3 protein expression was assessed by immunohistochemistry with mAb 236A/E7 
on a routinely fixed normal-tissue microarray containing 39 different human tissues 
and on whole sections of lymphoid tissues. Tissues included tonsil, spleen, bone 
marrow, brain, larynx, parotid gland, thyroid, gall bladder, liver, lung, skin, skeletal  
muscle, kidney, pancreas, stomach, colon, duodenum, small intestine, bladder, ovary, 
uterus, breast, placenta, prostate, testis, fetal liver and fetal thymus. There was no 
nuclear FOXP3 protein expression observed in the range of normal non-hematological 
tissues tested, with the exception of scattered positive lymphocytes in colon, stomach, 
and fallopian tube. These data are consistent with the reported restricted expression 
of FOXP3 within lymphocytes. Within hematological tissues there were much higher 
numbers of lymphocytes expressing FOXP3. The FOXP3+ cells were scattered within 
the interfollicular areas of tonsil (Figure 2A) and were occasionally seen within the 
follicular germinal centers (Figure 2A). Reactive lymph node contained many FOXP3+ 
cells and these were distributed throughout the tissue, including within the mantle 
zone and germinal centers of the secondary follicles. In spleen there were occasional 
FOXP3+ cells in the red pulp and there were increased numbers in the T cell areas 
around vessels (Figure 2A). There were many FOXP3+ cells in fetal thymus and in the 
mature thymus these were present predominantly in the medulla with only scattered 
FOXP3+ cells being present in the cortex (Figure 2A). In bone marrow a small number 
of FOXP3+ cells were also observed. To confirm the immunophenotype of the FOXP3+ 
cell population in situ within tissues, double-labeling studies were performed by 
immunofluorescent (Figure 2B) and immunoenzymatic techniques. These studies 
confirmed that in tonsil the FOXP3 protein was expressed exclusively in the CD3+ T cell 
population and no double-labeling of CD20+ B cells was observed. The majority of 
FOXP3+ cells were, as previously reported, both CD4+ and CD25+. However, double-
labeling identified a very small population of FOXP3+CD8+ cells and indicated that a 
minority of FOXP3+ cells were CD25- (Figure 2B) 
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1.6 FOXP3 is expressed in activated T cells 
There have been reports that FOXP3 expression is induced in activated T cells. Cytospin 
preparations of both resting and activated CD8+ and CD4+ human T cell clones were 
immunostained with FOXP3 mAb 236A/E7. FOXP3 protein expression was restricted to 
the nuclei of activated CD4+ and CD8+ T cell clones and was absent in the resting cells 
(Figure 2C). 
 
1.7 Frequency of FOXP3 expression in the human CD4+ population 
CD4+CD25+ and CD4+CD25- populations were purified from peripheral blood taken 
from three individuals without any known disease as described in the "Materials and 
Methods" section. Immunofluorescent labeling of FOXP3 expression was 
 
Figure 2. FOXP3 protein expression in 
normal human tissues. (A) Illustrates 
peroxidase immunolabeling of normal 
lymphoid tissues with the 236A/E7 
FOXP3 Ab. (B) Illustrates double-
immunofluorescent labeling of normal 
tonsil (g, green; r, red), confirming that 
the FOXP3 mAb recognizes 
predominantly CD4+CD25+ T cells. 
White arrows in the CD8 picture 
indicate the presence of rare 
CD8+FOXP3+ cells and in the CD25 
picture these indicate that a proportion 
of the FOXP3+ cells are CD25–. (C) 
Illustrates both activated and resting 
cells from the CD4+ T cell clone TB1 
(left) and the CD8+ clone 2D10 (right) 
stained for FOXP3 protein expression 
showing that activation induces FOXP3 
expression. 
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performedand and the numbers of FOXP3+ and FOXP3- cells were scored in each 
sample. Approximately half of the CD4+CD25+ population was FOXP3+ with a 
frequency of 55.7±5.2% (Figure 3A). In contrast, only 3.6±0.9% of the CD4+CD25- cells 
expressed FOXP3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite early difficulties with detecting endogenous FOXP3 protein by flow cytometry, 
a modified staining protocol that included a DNAse digestion step enabled FACS 
analysis of endogenous FOXP3 protein expression in the CD4+ population  and 
correlation with CD25 expression (Figure 3B). In peripheral blood, 95.7% (94.7–95.8) of 
Figure 3. Frequency of FOXP3 expression in CD4+ T cells. (A) Illustrates the frequency of FOXP3+ cells 
within the CD4+CD25+ (left) and CD4+CD25– (middle) populations purified from peripheral blood No 
staining of the CD4+CD25+ cells was observed with the secondary Ab alone (right). (B) The top left 
panel shows the FACS plots and gating of PBL labeled with CD4 and CD25. The top right panel 
represents the FOXP3 expression according to CD25 expression in the whole CD4 population. The 
FOXP3 expression in the gated populations is illustrated in the histograms. Quadrants are drawn 
based on isotype-matched control antibodies that gave <1% background. Representative of three 
separate experiments. 
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CD4+CD25high T cells expressed FOXP3 whereas only 34.9% (22.3–47.4) of 
CD4+CD25int T cells stained positive for FOXP3. No detectable staining was observed 
in the CD25- population or in resting CD8+ T cells (data not shown). As in the 
pheripheral blood lymphocytes, the majority (>95%) of thymic CD4+CD25high T cells 
express FOXP3 (data not shown). It is claimed that the commercially available hFOXY 
mAb is also suitable for FACS analysis of FOXP3 expression. However, we were unable 
to reveal FOXP3 expression amongst peripheral blood CD4+CD25+ cells using this 
reagent, suggesting it is not suitable for this application (data not shown). 
 
1.8 The FOXP3 mAb label functional CD4+CD25+T cells 
Although the double-labeling studies indicate that the FOXP3 mAb label predominantly 
CD4+ CD25+ T cell, their ability to detect T cells with functional regulatory activity was 
also confirmed. The immunophenotype of CD4+CD25+ T cells purified from peripheral 
blood using magnetic-bead selection was confirmed by flow cytometry (Figure 4A). 
Nuclear expression of the FOXP3 protein was confirmed by immunofluorescent 
labeling (Figure 4B), only the occasional FOXP3+ cell was observed in the CD25- 
population and no staining was observed when using the isotype-matched MR12 
control mAb (data not shown). These FOXP3+ cells were able to suppress the 
proliferation of CD4+CD25– T cells (Figure 4C) confirming that the mAb label functional 
CD4+CD25+FOXP3+ Treg cells. 
 
 
 
 
 
 
 
 
 
 
 
FOXP3  
Figure 4. The FOXP3 
236A/E7 mAb labels 
functional suppressor T cells. 
(A) Illustrates FACS 
confirmation of the 
CD4+CD25+ phenotype of 
the bead-sorted suppressor 
cells. (B) Shows the labeling 
of these CD4+CD25+ cells 
with the 236A/E7 FOXP3 
mAb.(C)The 
CD4+CD25+FOXP3+ cells are 
functionally able to suppress 
the proliferation of 
CD4+CD25–FOXP3– cells in a 
dose-dependent manner 
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1.9 FOXP3 expression in lymphomas 
Results of the examination of FOXP3 protein expression in lymphomas are shown in 
Table 3. In the 89 B- and 58 non-ATLL T-cell lymphomas, FOXP3 expression was only 
detected in the reactive T-
cell component (Figure 5A), 
without any noticeable 
staining in the tumoural 
cells (Figure 5B–D). The 
proportion of FOXP3-
positive reactive T-cells 
was highly variable, as 
compared with normal 
reactive tissue, ranging 
from almost a complete 
absence (usually seen in 
Burkitt’s lymphoma, Figure 
5D) to an evident infiltrate 
(common in follicular 
lymphoma, Figure 5C). In contrast, FOXP3 expression in the tumour cells was detected 
in 17/25 (68%) ATLL cases. In all these cases, FOXP3 expression was detected in 
CD4/CD25 positive cells (Figure 6 and Table 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: FOXP3 expression in normal 
and tumoural tissues. 
(A) Strong nuclear FOXP3 expression in 
reactive tonsil: most positive cells 
arelocated in the interfollicular T-cell 
area. (B) Low presence of reactive 
FOXP3þ T-cells in a case of peripheral T-
cell lymphoma; tumoural cells are 
negative. (C) Follicular lymphoma: a 
significant number of reactive FOXP3+ T 
cells are detected in neoplastic follicles; 
tumoural cells are negative. (D) Low 
presence of reactive FOXP3+ T cells in 
Burkitt’s lymphoma; tumoural cells are 
negative. 
 
Table 3. FOXP3 protein expression in lymphomas 
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Figure 6. FOXP3 expressions in ATLL. Skin infiltration by tumour cells (case number 10) showing a large 
proportion of CD4+, CD25+ and FOXP3+ cells (immunohistochemistry in paraffin-embedded tissue). 
 
 
Table 4. Study of FOXP3 expression in ATLL. 
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In terms of FOXP3 expression, three subgroups of ATLL cases could be defined taking 
into account both the proportion of positive cells and the intensity of the expression. 
The first subgroup (32% of 
patients) represents 
samples with strong 
nuclear FOXP3 expression 
in the majority of tumour 
cells (Figure 7A and B). 
The second group (36% of 
patients) exhibited 
intermediate expression 
of FOXP3 tumoural cells 
(Figure 7C and D), with a 
variable intensity of 
expression. Expression 
was weaker than 
observed in the first group 
and lower than observed 
for the scattered FOXP3+ 
cells present in the 
reactive component. 
Although in the majority 
of these cases, the 
distinction between 
tumoural and reactive 
FOXP3+ T-cells is 
straightforward, some 
samples needed detailed 
observation for evaluation. The presence of FOXP3 in tumoural cells was confirmed by 
double fluorescence analyses, showing that FOXP3+ nuclei are found in a minority of 
atypical CD25+ cells (Figure 7E). Finally, the third group of cases (32% of patients) 
 
Figure 7. FOXP3 expression in Adult T-cell leukaemia (ATLL) cases (A and B) 
Strong FOXP3 expression can be observed in the nucleus of the tumour 
cells. (C and D) Intermediate FOXP3 expression can be observed in some 
tumour cells. (E) Indirect double immunofluorescence in the same case 
displayed in panels c and d show nuclear FOXP3 expression (red) in a 
minority of large atypical CD25 positive cells (green). (F and G) No FOXP3 
expression is observed in the tumour cells of this ATLL case. 
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comprised ATLL samples where FOXP3 expression was clearly absent in the tumour 
cells (Figure 7F and G). 
 
1.10 Survival analysis 
As has been commonly reported, the course of ATLL is generally rapidly progressive 
and ultimately fatal with only one of the patients remaining alive at the follow-up (OS 
ranging from 1 to 133 months). The analysis of the relationship between FOXP3 
protein expression and survival only showed a near significant association with 
survival: patients with FOXP3-negative tumours tending to have better survival 
(median OS 41 months (range 1–
133) vs 7 months (range 2–65); 
P=0.060) than those with strong or 
intermediate FOXP3 expression 
(Figure 8). There was no significant 
difference in OS between the 
groups with intermediate or strong 
FOXP3 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Kaplan–Meier analysis of overall survival (OS) in ATLL patients grouped according to the expression of FOXP3: 
shorter survival in the FOXP3-positive group than in the FOXP3-negative group. 
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2. Results second project: Follicular helper T cells 
2.1 Immunostaining of SAP and NAT in normal lymphoid tissue  
The expression of the markers PD-1 and SAP in human lymphoid tissue (studied by 
single and double labeling techniques) is illustrated in Figure 9 and 10 and summarized 
in Table 5. Staining was performed on paraffin-embedded tissue sections. We 
confirmed that PD-1 was preferentially expressed by scattered cells in germinal centers, 
Figure 9. Expression of PD-1 by lymphoid cells. 
First row: Immunoperoxidase staining of human tonsil (seen at low, intermediateand high power) shows 
strong labeling of many cells within germinal centers. Second row: Double immunofluorescent staining 
of the PD-1-positive cells (red) in the germinal center co-express CD3 (green. Third row (left): Double 
labeling for PD-1 (red) and CD57 (green) in a germinal center (left). Double labeling for PD-1 (red) and 
CD8 (green) shows reciprocal expression of the two molecules in intrafollicular T cells (right). Fourth 
row: Double immunoenzymatic staining shows (left) the reciprocal expression of PD-1 (red) and PAX-5 
(nuclear, brown) in B cells, and also that a proportion of PD-1-positive germinal center T cells (red) 
express nuclear BCL6 (brown - example arrowed), and (right) that they lack the proliferation marker Ki-
67. 
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and these cells were shown by double labeling for CD3 to be T cells. Outside lymphoid 
follicles, the great majority of T cells were PD-1-negative (or only weakly positive). 
Additional double immunostaining showed that many PD-1-positive follicular T cells 
lacked CD57, CD8, the B-cell 
transcription factor PAX-5 and the 
proliferation marker Ki67 (Figure 9). 
However, approximately 20% of the 
PD1-positive follicular T cells 
expressed BCL6 (Figure 10) (although 
the proportion of BCL6- positive cells 
varied between germinal centers). 
The pattern of staining observed for 
the adaptor molecule SAP (Figure 10) 
was very similar to the pattern observed for PD-1, and double staining for the two 
markers showed essentially identical labeling within germinal centers. In extrafollicular 
regions SAP was expressed by occasional T cells that were PD-1 negative (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. SAP expression in 
normal human tonsil. 
Upper row: Immunperoxidase 
staining (viewed at low, 
intermediate and high 
magnification) shows a 
population of strongly stained 
cells within germinal centers with 
cytoplasmic and nuclear labeling. 
Second row: Double 
immunofluorescent staining for 
SAP (red) and CD3 (green) shows 
that many cells co-express these 
markers (white arrows). Cells 
expressing SAP with little or no 
CD3 are also present (yellow 
arrows) together with SAP-
weak/negative CD3-positive cells 
(green arrows). Third row: 
Double immunofluorescence 
labeling for SAP (green) and PD-1 
(red) shows that many cells in the 
germinal center co-express both 
molecules.  
 
Table 5. PD-1 and SAP in normal lymphoid tissue. 
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2.2 Western Blotting 
Western blotting of cell lysates from the YT line with the anti-PD-1 antibody NAT 
showed a single band with a molecular weight of approximately 47 kDa (Figure 11. 
Anti-SAP was tested against the YT line and also against a number of T-cell 
lymphoblastic cell lines (Jurkat, CCRF/CEM and Molt-4). A band of approximately 15 
kDa was found in each of these, accompanied in the case of Jurkat and CCRF/CEM with 
a second band of slightly smaller size (Figure 11). In contrast, the ALK-positive 
lymphoma cell line Karpas 299 was SAP-negative.  
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Immunostaining of PD-1 and SAP in neoplastic lymphoid tissue  
Among T-cell neoplasms, PD-1 and SAP were expressed over three quarters of the 
cases of AITL tested (42/49 and 59/69 cases, respectively) (Table 6 and Figure 12). The 
two markers were expressed independently of each other, with the result that almost 
95% of cases (40/42) expressed at least one of these markers (Table 6 and Figure 12). 
In addition to AITL both PD-1 and SAP were found in a minority of cases of peripheral 
T-cell lymphoma (5/30 and 13/37, respectively) (Table6 and Figure 11). Twenty-two 
cases that had been investigated for both markers were reviewed, and two cases, each 
of which was positive for both PD-1 and SAP (Table 6), showed some features  
 
 
 
Figure 11. Western blotting analysis 
of antibody NAT and SAP. 
Blotting with the former antibody in 
the NK cell-derived cell line YT shows a 
band with a molecular weight of 
approximately 47 kDa. SAP is 
detectable as a 15 kDa band in the YT 
line and also in three T-cell 
lymphoblastic cell lines (Jurkat, 
CCRF/CEM and Molt-4). Karpas 299 
(an ALK-positive lymphoma cell line) is 
negative. A second band, slightly 
smaller than the 15 kDa band, is also 
visible in the Jurkat and CCRF/CEM cell 
lines. 
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consistent with atypical AITL, but a 
further six cases (two double positive 
and four positive for SAP alone) 
appeared to be classic examples of 
peripheral T-cell lymphoma. Among the 
samples tested for only marker, a 
further six cases expressing PD-1 or SAP 
were identified, and two of these (one 
PD-1 positive, one SAP-positive) also 
had some features on review 
suggestive of possible AITL. All cases of 
AITL were immunostained for the CXCL13 
chemokine, and many cases contained 
CXCL13-positive neoplastic cells. However, 
background extracellular staining was 
often present and labeling in many positive 
cells was restricted to a single cytoplasmic  
dot. In consequence, evaluation of 
immunostaining in the majority of cases 
was more difficult than for and SAP. (Table 
6 and Figure 11). SAP was expressed in 
15/21 cases of T lymphoblastic lymphoma . 
(Table 6 and Figure 11) (whereas PD-1 was 
not found in this tumor type). In contrast, 
PD-1 was found in 5/9 cases of mycosis 
fungoides, whereas SAP expression was 
limited to a small minority of the 
neoplastic cells in 3/6 cases. (Table 6 and 
Figure 11). SAP and PD-1 were absent from 
 
 
Figure 11 .Immunostaining of T cell lymphomas for 
PD-1 and SAP. Top row: Two angioimmunoblastic T-
cell lymphomas (AITL) were positive for both 
markers. Second row: a case of peripheral T cell 
lymphoma expresses PD-1 and SAP. Third row: 
neoplastic cells in a case of mycosis fungoides 
express PD-1 (inset, high magnification) but are 
negative for SAP, with the exception of a few weakly 
positive cells (arrowed) (inset, high magnification). 
Fourth row: a case of T lymphoblastic lymphoma 
shows extensive nuclear staining for SAP. 
Table 6. PD-1 and SAP in Lymphomas 
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almost all of the non-Hodgkin’s B 
cell neoplasms investigated (Table 
6). 
PD-1 was found on the tumor cells 
in three diffuse large B-cell 
lymphomas (out of 98) and was 
also present in a minority of larger 
cells in cases of chronic 
lymphocytic leukemia/lymphoma 
(CLL). In six out of the 13 CLL cases, 
proliferation centers were recognizable and it was clear that the large PD-1 positive 
cells belonged to these structures. SAP was absent from all cases of non-Hodgkin’s B 
cell lymphoma, with the exception of three cases (out of 115) of diffuse large B-cell 
lymphoma (one of these three cases was PD-1 negative, the other two were not 
evaluated for PD-1) and proliferation centers in CLL (although the staining was weaker 
than for PD-1 and the number of SAP-positive cells was lower). Moreover, weak 
labeling of neoplastic cells for SAP was observed in four out of 14 cases of lymphocyte 
predominant Hodgkin’s disease (in approximately just over half of the tumor cells). 
Reed-Sternberg cells were SAP-negative with the exception of one case (out of 21) of 
classical Hodgkin’s disease in which approximately 50% of the tumor cells were weakly 
to moderately positive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Comparison  between PD-1 and SAP 
Lymphomas 
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2.4 Infiltrating cells 
In all studied B-cell lymphomas, occasional non-neoplastic cells carrying PD-1 and SAP 
were observed. The highest percentage of PD-1 negative and SAP positive infiltrating 
cells was found in follicular lymphomas, lymphocyte predominant Hodgkin’s disease 
(Figure 12) and in some cases of diffuse large B-cell lymphoma. In the first disease, the 
number of these infiltrating cells varied widely from case to case and was independent 
of histologic grade. In lymphocyte predominant Hodgkin’s disease, PD-1 and SAP were 
positive in infiltrating cells, and in many cases these cells formed rosettes surrounding 
the neoplastic cells (Figure 12). Incontrast, in classical Hodgkin's disease, PD-1 positive 
or SAP positive rosettes were found in only a minority of cases (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Immunostaining of T cell 
lymphomas for PD-1 and SAP.  
Top row, left: The positive CD3 
staining of tumor cells in a case 
diagnosed as typical peripheral T-cell 
lymphoma highlights its interfollicular 
growth pattern and the preservation 
of lymphoid follicles. Top row, right: 
the tumor cells in the same case 
show weak to moderate expression 
of PD-1. Note the difference in terms 
of intensity between the strongly 
positive normal T cells (arrowed) in a 
germinal center and the weaker 
staining of tumor cells (as also 
illustrated at high magnification in 
the inset) adjacent to the unstained 
mantle zone cells. Second row: in a 
case of follicular lymphoma, many 
PD-1- and SAP-positive cells are seen 
in a neoplastic follicle. Third row: in a 
case of lymphocyte predominant 
Hodgkin’s disease (LPHD) many 
reactive lymphocytes are PD-1 
negative and SAP-positive. The insets 
show cells expressing these markers 
forming rosettes surrounding the 
tumor cells. Third row: in a case of 
classical Hodgkin’s disease (cHD) PD-1 
and SAP are seen in many reactive 
lymphocytes, and the insets show 
neoplastic cells surrounded by 
rosettes of PD-1 negative and SAP-
positive T cells. 
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2.5 PD-1, a Follicular T-cell Marker useful for recognizing nodular 
lymphocyte-predominant Hodgkin lymphoma  
 
2.5.1. PD-1 in the differential diagnosis of B cell Lymphomas 
The potential diagnostic value of PD-1 was explored in a series of 152 cases diagnosed 
as nodular sclerosis Hodgkin lymphoma, mixed cellularity Hodgkin lymphoma, 
lymphocyte rich classic Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin 
lymphoma (NLPHL), and T-cell/histiocyte rich B-cell lymphoma (T/HRBCL). The results 
obtained are summarized in Table 8. 
 
                                      Table 8. Main immunohistochemical features 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.2 PD-1 expression in progressively transformed germinal centers 
(PTGCs) 
The expression of PD-1 (NAT-105) was studied in paraffin-embedded tissue sections of 
4 lymph nodes and 2 human tonsils biopsies. PD-1 (NAT-105) was selectively expressed 
by T cells in germinal centers, localized predominantly in the periphery of the germinal 
centers as a rim in the outer zone. Outside of lymphoid follicles, the great majority of 
the T cells were negative (Figure 13 A–C). PD-1 (NAT-105) was expressed by T cells in 
germinal centers, which were more numerous than normal or reactive germinal 
centers. In one case (1/7), these cells were distributed around B cells of centroblastic 
appearance, sometimes clearly in the form of T-cell rosettes (Figure 13 D–F). 
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2.5.3 PD-1 expression in lymphocyte rich classic Hodgkin lymphoma 
(LRCHL) 
A relatively large group of cases diagnosed as LRCHLs displayed follicular T-cell rosettes 
surrounding tumoral classic Reed-Sternberg cells. With CD57, 53.8% of the cases (7/13) 
presented follicular T-cell rosettes (Figure 14 A-B), whereas these were present in 
76.9% of PD-1 cases (10/13) (Figure 14C). All cases with CD57-positive T-cell rosettes 
were also PD-1 positive. 
 
  
           
 
 
 
Figure 13. Reactive lymphoid follicle (A) with germinal centers stained with CD57 (B) and PD-1 (NAT-
105) (C). PTGC (D) with germinal centers with frequent T cells stained with CD57 (E) and PD-1 (NAT-
105), depicting isolated T-cell rosettes (F). 
 
Figure  14. LRCHL (A) with CD57-negative (B) and PD-1 (NAT-105)-positive T-cell rosettes (C). 
NLPHL (D) with CD57-negative (E) and PD-1 (NAT-105)-positive T-cell rosettes (F). 
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To explain the differences between the cases with and without rosettes, clinical and 
immunophenotype data (Tables 9 and 10) were sought wherever possible. Clinical data 
obtained from 9 of 10 cases demonstrated that, independent of the presence of T-cell 
rosettes, most of the cases were diagnosed at a localized stage (stages I or II) and 
without B symptoms. Two of three cases displaying T-cell rosettes also showed B 
symptoms but none of these cases recurred or needed salvage therapy. No T-cell 
rosettes were observed with BCL6. 
 
 
Table 9. Summary of the LRCHL clinical data 
                 
 
 
 
 
 
 
 
 
 
 
    
 
2.5.4 PD-1 expression in nodular lymphocyte-predominant Hodgkin 
lymphoma (NLPHL) 
In 75.9% (44/58) of the cases of NLPHL, CD57 distinct rosettes surrounding tumoral 
cells were seen (Figure 14D-E). With PD-1 (NAT-105), the rosettes could be 
demonstrated in more cases than CD57, appearing in 98.3% (57/58) of the cases 
(Figure 7F). Moreover, 7 cases showed CXCL-13–positive T-cell rosettes. BCL6 was 
positive in the tumoral cells in 6/58 cases. No BCL6–positive T-cell rosettes were 
observed. 
 
2.5.5 PD-1 expression in nodular lymphocyte-predominant Hodgkin 
lymphoma (NLPHL) with diffuse areas 
With regard to the cases of NLPHL with diffuse areas, CD57 demonstrated T-cell 
rosettes in all the cases (7/7), but limited to the nodular areas (Figure 15 A-B). PD-1 
 
 
 
Table 10. Main Phenotypic features of LRCHL 
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was positive in fewer cases than was CD57. It was also limited to the nodular areas and 
was only positive in 71.4% of the cases (5/7). In these cases, the intensity of the 
immunostaining with PD-1 seemed to diminish gradually from the nodular to the 
diffuse areas (Figure 15C). BCL6 was positive in the tumoral cells in most of the cases 
(6/7), but not in the T-cell rosettes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.6 NLPHL versus T/HRBCL 
The cases not clearly defined either as NLPHL or T/HRBCL, 80% (4/5) of them displayed 
PD-1-positive T-cell rosettes (Figure 15D and E). As in most of the other types of 
lymphomas, CD57 detected fewer cases with follicular T-cell rosettes (60%; 3/5) 
(Figure 15E). BCL6 was positive in the tumoral cells in all cases. 
 
2.5.7 Other types of lymphoma 
Other types of lymphoma were included in this study for comparison, including NSHL, 
MCHL and T/HRBCL; none of them displayed T-cell rosettes either with CD57 or with 
PD-1. 
 
Figure 15. NLPHL with diffuse areas (A) with CD57 (B) and PD-1 (NAT-105)-positive T-cell rosettes in the 
nodular areas (C). NLPHL versus T/HRBCL (D) with CD57-negative (E) and PD-1 (NAT-105)-positive T-cell 
rosettes (F). 
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2.5.8 Other observations 
Three cases of NSHL, 1 case of LRCHL and 1 case of NLPHL versus T/HRBCL without T-
cell rosettes positively immunostained for CD57 in the tumoral cells. This aberrant 
expression of follicular T-cell markers in the tumoral cells was also detected using 
CXCL-13. Thus, we diagnosed 1 case of NSHL, 7 cases of NLPHL and 2 cases of T/HRBCL 
with CXCL-13-positive tumoral cells. No relevant features were seen with CD10. 
Statistical analysis demonstrated that PD-1 was able to detect significantly more cases 
with T-cell rosettes, both in NLPHL and LRCHL groups, than CD57 and CXCL- 13 (P<0.05). 
The presence of PD-1–positive T-cell rosettes was significantly higher in NLPHL group 
than in LRCHL group (P<0.05). However, there was no difference with CD57 (P>0.05). 
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1. Discussion fist project 
1.1 FOXP3 as a human Treg marker 
CD25+CD4+ Tregs represent a unique population of lymphocytes capable of powerfully 
suppressing immune responses. In healthy individuals, the most important role of Treg 
cells is to maintain immune tolerance to self-antigens, which prevents development of 
autoimmune disease. It is now recognized that Tregs have a crucial role also in 
transplantation, allergic responses, microbial and cancer immunity (41, 72-74).  
Since the description of suppressor T cells (now called Treg) in the early 1970s, 
considerable progress has been made in the characterization of this cell type. The 
Identification, in 2003, of FOXP3 as a master regulator of Tregs development was 
fundamental for a more precise definition and characterisation of this cell population 
(75). At the time, due to the lack of Treg-specific markers, little was known about the 
presence or distribution of Tregs in normal and tumoral human tissue.  
To address these issues, we generated a panel of 7 monoclonal antibodies that 
specifically recognise the human FOXP3 protein. These mAbs were tested in a variety 
of commonly used immunological techniques, and we showed that they can be used 
for immunohistochemistry on frozen and paraffin-embedded tissues, western blotting 
and flow cytometry. Moreover, two of these mAbs can also detect the murine FOXP3 
protein. The use of these antibodies has allowed us to characterise in detail the human 
FOXP3 expression at the single cell level in both lymphoid tissue and peripheral blood 
for the first time. 
Immunolabelling studies on reactive human tissues showed that FOXP3 expression was 
restricted within the lymphoid population. In tonsil and lymph node, strong nuclear 
FOXP3 expression was detected in approximately 5% of interfollicular T cells, even 
though FOXP3+ T cells were occasionally seen within the germinal centre.  
Within lymphocytes, double labelling studies have confirmed that the majority of 
FOXP3+ cells were indeed CD4+ CD25+ cells, and that approximately half of the whole 
CD4+CD25+ population in peripheral blood expressed FOXP3. A small population of 
CD4+CD25-FOXP3+ lymphocytes was also identified. To investigate the correlation 
between this FOXP3+ cell population and CD25 expression, we designed a modified 
staining protocol (that includes a DNAse digestion step) that enables endogenous 
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FOXP3 protein detection by flow cytometry. We found that 96% of CD4+ CD25high 
peripheral blood lymphocytes (PBL) were FOXP3 positive, whereas only 35% of 
CD4+CD25low PBL expressed FOXP3. These data confirmed that, in humans, Treg activity 
is mostly restricted to the CD4+CD25high T cell population, and that CD4+CD25low are a 
more heterogeneous population that include also activated CD25+ lymphocytes. We 
also described the presence of FOXP3 protein in a small number of CD4+CD25- FOXP3+ 
lymphocytes, as well as in a few CD8+ T cells. Subsequent studies have confirmed the 
presence in humans of CD8+CD25+FOXP3+ cells with regulatory activity and able to 
suppress immune response (76). However, a more complete characterisation of this 
cell subtype remains to be done to clarify the function and rule of this cell subtype in 
the immune system. 
Next, we were interested in determine whether the CD4+CD25+ FOXP3+ cells 
population selected using our FOXP3 mAbs were able to suppress CD4+CD25- cells. 
The results obtained confirmed that FOXP3 antibodies can be used to label functional 
CD4+CD25+FOXP3+ regulatory T cells. 
The application of our FOXP3 mAbs for FACS analysis has opened new avenues in the 
investigation of the function and the differentiation of FOXP3+ Treg. Although 
expression of the transcription factor FOXP3 currently constitutes the best-known 
marker for Tregs, a transient expression of this molecule is also observed in activated 
non-Treg cells.  The search for a specific cell surface marker for FOXP3+ cells is still an 
active and important area of interest.  
 
1.2 Evaluation of FOXP3 expression in tumour cells 
Nuclear FOXP3 protein expression in tumour cells was first reported in 2004 by Karube 
et al. (77), who found FOXP3 expression in patients affected by adult T-cell 
leukaemia/lymphoma (ATLL), an immunosuppressive T cell malignancy characterised 
by a CD4+CD25+ immunophenotype (65). 
In order to investigate the expression of FOXP3 protein in lymphomas we have 
analyzed a large set of B and T lymphomas using our FOXP3 236A/E7 mAb, which is 
able to recognise FOXP3 protein in paraffin embedded tissues samples. In agreement 
with Karube’s observation, our results showed that FOXP3 expression in malignant 
lymphoma cells is restricted to a subpopulation of patients with ATLL, while in the 
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other lymphoma types analysed, FOXP3 expression was only detected in the reactive T 
cell population present in the tumour microenvironment.  
ATLL is a lymphoproliferative disorder caused by human T-cell lymphotropic virus type-
1 (HTLV-1) infection, which is highly endemic, especially in southern Japan and the 
Caribbean basin. In general, ATLL shows rapid progression, drug resistance and poor 
prognosis (78). The diversity in the prognosis of patients makes ATLL an extremely 
complex type of disease, and the existence of a FOXP3 positive ATLL population 
confirmed the heterogeneity of ATLL in terms of pathological, biological and clinical 
futures. We were interested in figuring out whether the expression of FOXP3 could be 
associated with the clinical course of the diseases. To address this question we 
performed correlation studies between FOXP3 expression and overall survival in ATLL 
patients, finding that FOXP3+ ATLL may present a more aggressive clinical course, 
although the difference was not statistically significant. From these findings, we 
hypothesized that FOXP3+ ATLL could modulate the immune response against the 
tumour, and could be directly implicated in the generation of the immunodeficiency 
state commonly associated with ATLL patients (79).  
The expression of FOXP3 and its correlation with clinicopathological course was further 
investigated by Karube et al. in a larger series of patients (80). This new study 
confirmed that FOXP3 expression was confined to a subgroup of FOXP3+ ATLL, and no 
differences in overall survival determined by FOXP3 expression were found. This work 
also demonstrated that FOXP3 expression in ATLL correlated with certain 
morphological features (including chromosome abnormalities and proliferation of EBV-
positive cells), and concluded that the presence of FOXP3 is associated with patients 
presenting an immunosuppressed clinical state (80).  
Although the mechanisms generating the immunodeficiency in ATLL remain unknown, 
we could speculate that one of the processes implicated in the immunosuppresion 
state could be the presence of FOXP3 protein in ATLL tumour cells increasing the 
expression of immunoregulatory molecules on their surfaces, and by the production of 
immunosuppressive cytokines able to suppress effectors T cells. 
On the other hand, the possible mechanisms implicated in ATLL origin are still unclear. 
Two possible mechanisms have been proposed. As a first hypothesis, HTLV-1 virus 
could directly target Tregs, and changes in FOXP3 expression could be a result of tumour 
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transformation. Alternatively, leukemic cells could originate after infection of 
CD4+CD25- T cells, and they could subsequently acquire a Treg-like phenotype. Support 
for the latter hypothesis is provided by recent data demonstrating that HTLV-1 
infection of CD4+CD25- T cells from healthy donors induces a Treg phenotype by up 
regulating CD25 protein, FOXP3 expression and TGF-β secretion (81).   
In conclusion, while FOXP3 expression in ATLL may not predict survival, a significant 
correlation can be found with the pathological immunodeficient state, illustrating that 
FOXP3 positive ATLL may function as Treg-like type of tumour. The use of the FOXP3 
mAbs generated in this work in the routine diagnostic laboratories could help the 
identification of ATLL cases worldwide, since FOXP3 expression in tumour cells seems 
to be restricted to this particular tumour type. 
 
1.3 FOXP3 expression in haematological malignancies and tumour 
microenvironment 
The tumour microenvironment is essential for tumour cell proliferation, angiogenesis, 
invasion, and metastasis by providing survival signals and an appropriate environment 
for tumour cells. The microenvironment specific cell composition seems to play an 
essential role in this scenario, harbouring the ability to develop successful immune 
responses or, on the contrary, leading to immune evasion and even promoting tumour 
growth (82). 
The cellular composition of the tumour microenvironment, particularly the amount of 
tumour infiltrating Tregs, can significantly mediate cancer immunity. The first report 
indicating the presence of CD4+CD25+ Tregs in human tumour microenvironment 
emerged in 2001, when Woo et al. reported an increased percentage of Tregs in lung 
and ovarian cancer (83, 84). Since then there has been an explosion of literature 
describing the presence of Tregs in cancer and its correlation with the clinical outcome. 
Therefore, in the majority of patients afflicted with solid tumours (such as stomach, 
lung, and ovary cancers), high levels of tumour-infiltrating Tregs were associated with a 
poor prognosis (85), whereas in haematological malignancies, tumour-infiltrating Tregs 
have been demonstrated to have different influences on the clinical outcome. 
Thus, in a study run in collaboration with Drs. Piris and Alvaro, the use of our FOXP3 
236A/E7 mAb as allowed to assess the relevance of Tregs and cytotoxic T lymphocytes 
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populations (defined by TIA-1 and Granzyme B) in the reactive background of 
Hodgkin’s lymphoma (HL) and its correlation with patient outcome. This study 
concluded that low infiltration of FOXP3+ cells in combination with high infiltration of 
TIA-1+ cells represent an independent prognostic factor negatively affecting the 
survival in this type of lymphoma (see Appendix 1). Furthermore, when the disease 
relapses and progresses, a larger number of TIA-1+ cells and a lower proportion of 
FOXP3+ cells are present in the reactive background of the tumour. 
A similar result was obtained in a second collaborative study with Dr. Carreras, who 
reported that follicular lymphoma patients (FL) with higher FOXP3+ Tregs numbers in 
their tumours showed a better response to therapy and improved overall survival (see 
Appendix 2). This work also described that the number of Tregs seemed to be constant 
in patients who maintained the same cytological grade, but the number was 
dramatically reduced where the tumour transformed into a diffuse large B cell 
lymphoma, a more aggressive type of disease (see Appendix 2).  
In conclusion, in contrast with most studies in solid tumours, an increased number of 
Tregs seems to be associated with prolonged survival in HL and FL, suggesting that 
FOXP3+ cells reflect a different biologic aspect of Tregs in this type of malignancies. 
These findings suggest that Tregs could promote or constrain tumour cell development 
depending of the distribution and activation status of the different cells subpopulation 
present in the tumour microenvironment. 
We could hypothesize that in those lymphomas that are invaded by a large 
inflammatory population, the tumour cells could receive stimulatory signals directly 
from surrounding inflammatory cells via secreted cytokines and by cell-cell signalling, 
thus promoting tumour growth and survival (86). We may speculate that in these cases 
the presence of a high number of regulatory T cells could modulate the 
interrelationship between tumour and inflammatory cells, hampering tumour cell 
development. Another possible scenario may be that Tregs might have a direct effect on 
B cells, probably suppressing B cell proliferation by inducing cell death via a cytotoxic-
dependent pathway (30, 87, 88). 
In any case, all these data are indicative of our incomplete knowledge about the exact 
mechanisms and the role played by Treg cells in the complex pathophysiology and 
immune surveillance of lymphoid malignancies. The FOXP3 mAbs generated and 
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characterized during this work could help in elucidating the mechanisms by which Tregs 
accumulate and function in the tumour microenvironment, as well as in the 
identification of attractive therapeutic targets potentially useful to fight against 
tumour-induced immune suppression. Moreover, in case of HL and FL, the detection of 
a high number of FOXP3+ cells by using these antibodies, is already being applied in 
the clinical setting as a reliable prognostic marker able to predict improved survival. 
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2. Discussion second Project  
2.1 PD-1 and SAP in Angioimmunoblastic T cell Lymphoma  
 
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and complex lymphoproliferative 
disorder associated with deregulation of B-cells within a unique malignant 
microenvironment (89). Non-neoplastic cells represent the major component of ATLL 
and are composed by a polymorphic inflammatory infiltrate containing small 
lymphocytes, large lymphoid blasts and follicular dendritic cells, as well as an increased 
vascular proliferation (90).  
 AITL usually has a very aggressive course, probably determined by the deregulated 
immune/inflammatory response rather than by a direct complication of the tumour 
itself (91). Since the same morphological features can be seen in other conditions, such 
as in atypical reactive processes, Hodgkin lymphoma, B-cell lymphomas, and other 
peripheral T-cell lymphoma, the diagnosis of this type of lymphoma remains quite a 
challenge. 
Recent advances in the study of AITL are coming from gene expression profiling studies 
carried out on peripheral T-cell lymphomas, which have identified TFH as the putative 
cell of origin of AILT and PD-1 and CXCL13 as the best markers for these T cells subsets 
(44, 92). 
A further relevant molecule that appears to be suitable for identifying TFH cells is the 
signaling lymphocytic activation molecule-associated protein (SAP), which has been 
described to be extremely important for TFH physiology, being indispensable for TFH cell 
signaling and critical for B-T conjugates formation (93). The expression of PD-1 and SAP 
was not been investigated in human lymphomas due to the lack of antibodies reacting 
with formalin-fixation resistant epitopes. In an effort to better define the expression 
and the diagnostic value of PD-1 and SAP molecules in lymphomas we have generated 
a specific mAb (clone name NAT105) able to recognize PD-1 protein in paraffin 
embedded tissue, and we have evaluated its expression in a large set of reactive and 
tumour samples. A commercially available antibody against SAP molecule was also 
evaluated in this study.  
Initially, we found that PD-1 expression was restricted to lymphoid cells and in 
particular to T cells located in the apex of the light zone in germinal centers of 
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secondary B-cell follicles. Also, a proportion of lymphocytes in the interfollicular area 
expressed lower amounts of PD-1. 
We confirmed that PD-1 and SAP are co-expressed in the same cell type in the GC, 
although the presence of scattered SAP+PD1- cells in the interfollicular areas was also 
detected. This finding suggests that SAP could be induced slightly in advance of PD-1, 
maybe before TFH enter in the GC. 
Among T cell lymphomas, SAP and PD-1 were expressed by the neoplastic cells in the 
majority of cases of AITL. These data confirm the previous reports that proposed that 
this disease arise from TFH cells (94, 95).   
We reported that SAP and PD-1 are expressed in a minority of T cell lymphomas other 
than ATLL and in a minority of cases of mycosis fungoides, a cutaneous neoplasm that 
do not originate from TFH cells. Further studies are needed to redefine those cases of 
PTCL that lack the classical futures of AITL but do also express SAP and PD-1, raising the 
question of a possible relationship between these lymphoma types. 
We also described that SAP/PD-1 were not expressed in the majority of B cell 
neoplasms, with the exception of a few cases of DLBCL, where their presence could be 
due to an occasionally upregulation of these genes in non-B cells, as a result of the 
neoplastic transformation. SAP expression was also found in more than two thirds of 
acute lymphoblastic leukemia of T cell origin, in concordance with our observation that 
cortical thymocytes contain this protein. 
In conclusion, our observations provide additional support from the idea that AITL 
derives from TFH cells, since a large majority of them express SAP and PD-1 molecules. 
We also believe that neoplastic transformation of TFH may contribute to the 
immunodeficiency and immune dysfunction commonly seen in AITL. The defective T 
cell response could be partially explained by the secretion of TFG-β and IL-10 by TFH 
resulting in the inhibition of the proliferation and function of conventional CD4 T cells, 
and consequently resulting in a defective T cell response. In any case, the complex 
network established among the tumors cells and the various component of the 
reactive tumor microenvironment is still not well understood. We believe that TFH may 
play a major role in modulating the growth and survival of neoplastic cells, since this 
cell type is involved in the recruitment, activation and differentiation of B cells, as well 
as in modulating other T cell subsets and in promoting vascular proliferation (5, 96).  
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In summary, PD-1 in combination with CXCL13, ICOS and Bcl6 represents the most 
useful and robust immunohistochemical TFH marker able to identify this cell subtypes in 
several experimental settings. Also, PD-1 is extremely useful in the diagnosis of AITL, 
helping to differentiate this condition from lymphoid hyperplasia and PTCL. 
 
2.2 PD-1 as a tool for the differential diagnosis of nodular lymphocyte-
predominant Hodgkin lymphoma 
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a disease entity 
distinct from classical Hodgkin lymphoma (cHL), were neoplastic cells (referred as LP 
cells) are B cells of germinal centre origin usually distributed in large nodular structures 
of small B cells, scattered histiocytes in association with a network of follicular 
dendritic cells (FDCs) (97), (98).Furthermore, this type of lymphoma is characterized by 
an increased number of germinal center-derived CD57+ T cells, which are closely 
associated with LP cells, often forming rosettes around them. These cells also express 
markers present in TFH cells such as BCL6, IRF4/MUM1 and c-MAF (99), suggesting that 
these reactive cells could be TFH cells. 
The differential diagnosis between NLPHL can constitute a real challenge, since this 
type of lymphomas shares several morphological and immunophenotypic similarities 
with lymphocyte-rich classical Hodgkin lymphoma (LRCHL) and T cell /histiocyte-rich B 
cell lymphoma (T/HRBCL).  
Due to the complexity of the differential diagnosis of NLPHL we assessed the 
diagnostic and prognostic potential of several TFH markers (CD10, BCL6, CXCL13, CD57 
and PD-1) for the identification of T-cell rosettes, since their presence have been 
proposed as a diagnostic feature of NLPHL. 
In our study we found that PD-1-positive and CD57-positive rosettes were present in 
98% and 76% of NPHL cases respectively, showing that PD-1 is an effective and 
sensitive marker for this disease. Noticeably, these results confirm that in this 
malignancy, tumor cells reside and proliferate in close association with a cellular 
environment that retains the key features of a normal GC cellular microenvironment.  
Interestingly, we describe for the first time that the presence of PD-1 positive rosette 
was not a unique feature of NPHL, but we also found it in several cases of LRCHL. 
LRCHL is the subtype of cHL the most difficult to differentiate from NLPHL, and 
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misclassification of this type of tumor has been reported (100).  The presence of PD-1 
positive rosettes suggests that LRCHL could be a distinct subtype of cHL with 
characteristics common to both types of lymphomas (101). Furthermore, the atypical 
tumors cells in both lymphomas share common characteristics, such as overexpression 
of B cell transcription program markers, and the presence of a follicular T cell 
background, suggesting a close biological relationship between these entities.  
In any case, the most crucial need of a differential diagnosis of NLPHL is with respect to 
T/HRBCL, since the latter represents a clearly distinct clinicopathologic entity with a 
more aggressive course, and requiring a different therapeutic management. Both 
T/HRBCL and NLPHL contain a reduced number of tumour cells that display features of 
germinal center B cells, but they differ notably in the non-neoplastic 
microenvironment (102). 
In our study, none of the cases that had been diagnosed as T/HRBCL displayed rosettes 
stained either with CD57 or with PD-1 mAbs, whereas the borderline cases between 
the two lymphoma types seemed to have follicular T-cell rosettes, thus more closely 
corresponding with the characteristics of the NLPHL diagnosis group.  
We also reported the superior diagnostic value of PD-1 in comparison with CD57, BCL6 
and CXCL13. In most types of lymphoma in which T-cell rosettes were present (LRCHL, 
NLPHL vs. T/HRBCL), PD-1 mAb showed improved staining results, leading to the 
conclusion that PD-1 should be used as a routine immunomarker especially for the 
diagnosis of NLPHL and LRCHL. 
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Conclusion first project  
 
1. We have identified and documented for the first time the expression of FOXP3 protein at 
single cell level in both lymphoid tissue and peripheral blood, showing that FOXP3 is as a 
specific marker of normal and tumoral Treg. 
 
2. The use of our panel of FOXP3 mAbs allows the characterisation of human FOXP3 protein in 
a variety of commonly used immunological techniques; in particular its application for FACS 
analysis has opened new avenues in the investigation of Treg biology and function. 
 
3. FOXP3 expression in malignant lymphoma cells is restricted to a subpopulation of patients 
with ATLL, while in the other lymphoma types studied, FOXP3 expression was only detected in 
the reactive T cell population present in the tumour microenvironment.  
Conclusion second project 
1. We have identified and documented the expression of PD-1 and SAP protein at single cell 
level in lymphoid tissue, showing that PD-1 and SAP mAbs are specific markers of normal and 
tumoral TFH cells.  
 
2. PD-1/SAP expression in malignant lymphomas showed that the majority of AITL cases 
expressed at least one of these markers, providing additional evidence that AITL arises from 
TFH and that PD-1 is likely to be an extremely valuable tool in the diagnosis of this disease.  
 
3. PD-1 is an excellent marker for the identification of the characteristic T-cell rosettes 
surrounding neoplastic B-cells in nodular lymphocyte-predominant Hodgkin lymphoma (NPHL). 
 
4. The presence of PD-1 positive rosettes is not a unique feature of NPHL, since we also found 
this in several cases of lymphocyte-rich classical Hodgkin lymphoma (LRCHL), suggesting a 
close biological relationship between these entities. 
 
5. PD-1 has an additional useful application in the differential diagnosis of NLPHL, since it can 
help to discriminate between NPHL and T/HRBCL, which lacks the presence of T cell rosettes. 
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Conclusiones del primer proyecto  
1. Hemos descrito y documentado por primera vez la expresión de la proteína FOXP3 a nivel 
celular, tanto en tejido linfoide como en sangre periférica. 
2. El empleo de nuestro panel de anticuerpos contra FOXP3 permite el estudio de esta 
proteína mediante una gran variedad de técnicas inmunológicas. En particular, su aplicación en 
citometría de flujo ha abierto nuevas vías en la investigación de la biología de los linfocitos Treg.  
3. La expresión de FOXP3 en linfocitos tumorales se encuentra restringida a una subpoblación 
de pacientes con ATLL, a diferencia de los otros tipos de linfomas estudiados, donde la 
expresión tan sólo fue detectada en una población de células T reactivas presentes en el 
microambiente tumoral.  
 
Conclusiones del segundo proyecto  
1. Hemos descrito y documentado por primera vez la expresión de las proteínas PD-1 y SAP a 
nivel celular en tejido linfoide, demostrando que ambos marcadores son específicos de las 
células TFH normales y tumorales. 
 2. El estudio de la expresión de PD-1/SAP en linfomas ha mostrado que la mayoría de los casos 
de AITL expresan al menos uno de estos marcadores, dato que refuerza la hipótesis de que los 
AITL derivan de las células TFH. PD-1 es por tanto una herramienta muy valiosa en el 
diagnóstico de esta enfermedad. 
 3. El anticuerpo generado contra PD-1 es un excelente marcador de las rosetas linfocitarias T 
que rodean las B neoplásicas, característica clave en el diagnóstico del linfoma de Hodgkin de 
predominio linfocítico (NPHL).   
4. Por primera vez hemos descrito que la presencia de rosetas PD-1 positivas no es una 
característica exclusiva del NPHL, sino que también se puede encontrar en un porcentaje 
elevado de linfomas de Hodgkin clásico rico en linfocitos (LRCHL), lo que sugeriría una estrecha 
relación biológica entre ambas entidades. 
5. PD-1 tiene un papel adicional para el diagnóstico diferencial entre NPHL y T/HRBCL, al 
carecer este último de las características rosetas. 
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